≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Postzoster neuralgia

DOID EFO Endpoint Browser PheWeb

G6_POSTZOST

cranial nerve palsy: Injury to any of the cranial nerves or their nuclei in the brain resulting in muscle weakness.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

2 out of 7 registries used, show all original rules.

633

4. Check minimum number of events

None

633

5. Include endpoints

None

633

6. Filter based on genotype QC (FinnGen only)

608

Control definitions (FinnGen only)

Control exclude
G6_NERPLEX

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 3542 2189 1325
Only index persons 3234 2038 1196
Unadjusted period prevalence (%)
Whole population 0.05 0.06 0.04
Only index persons 0.06 0.07 0.05
Median age at first event (years)
Whole population 75.27 76.62 72.99
Only index persons 74.95 76.35 72.58

-FinnGen-

Key figures

All Female Male
Number of individuals 608 361 247
Unadjusted period prevalence (%) 0.12 0.13 0.11
Median age at first event (years) 72.76 72.29 73.44

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
633
Matched controls
6330
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
B02.9
ICD-10 Finland
Zoster without complication
21.9
307.7
305
258
G53.0
ICD-10 Finland
Postzoster neuralgia
467.5
307.7
284
11
G53.0*B02.20
ICD-10 Finland
Trigeminal neuralgia after shingles
849.1
242.2
223
*
J05AB11
ATC
valaciclovir; oral
11.6
217.8
332
548
N03AX12
ATC
[U] gabapentin; oral
11.3
208.3
316
515
B02.8
ICD-10 Finland
Zoster with other complications
74.0
183.8
100
16
N03AX16
ATC
[U] pregabalin
9.3
180.0
362
797
J05AB01
ATC
aciclovir; systemic
8.8
170.6
377
908
G53.0*B02.21
ICD-10 Finland
Postherpetic geniculate ganglionitis
976.9
159.9
150
*
S70
ICPC
Herpes zoster
14.0
112.2
111
95
G530, B028,
ICD-10 Finland
1225.8
108.8
103
*
N02BF01
ATC
gabapentin; oral
7.4
100.8
175
309
B02
ICD-10 Finland
Zoster [herpes zoster]
9.7
97.3
126
158
N06AX21
ATC
duloxetine; oral
7.0
94.5
174
325
N02BF02
ATC
pregabalin; oral
7.7
80.7
127
199
N02AX02
ATC
tramadol; systemic, rectal
4.5
73.4
422
1939
G56.0
ICD-10 Finland
Carpal tunnel syndrome
10.3
62.2
73
79
H19.2*B02.3
ICD-10 Finland
Keratitis and keratoconjunctivitis (interstitial) in zoster
28.4
58.6
40
15
B02.20
ICD-10 Finland
Herpes zoster trigeminal neuralgia
141.4
49.6
52
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.8
48.7
198
680
H02AB06
ATC
prednisolone; systemic
3.2
42.5
406
2284
N06AX16
ATC
venlafaxine; oral
3.9
39.6
136
411
G50.0
ICD-10 Finland
Trigeminal neuralgia
54.9
39.1
46
9
N03AF01
ATC
carbamazepine; oral, rectal
5.7
38.8
77
149
N02AA05
ATC
oxycodone; systemic
3.0
35.9
216
922
M79.2
ICD-10 Finland
Neuralgia and neuritis, unspecified
9.5
34.6
42
47
N02AJ06
ATC
codeine and paracetamol; systemic
2.8
34.5
327
1766
N03AX09
ATC
lamotrigine; oral
6.8
34.3
56
89
G51.0
ICD-10 Finland
Bell palsy
179.3
33.0
34
*
A01
ICPC
Pain general/multiple sites
3.6
32.3
124
401
B02.21
ICD-10 Finland
Herpes zoster neuralgia in another cranial nerve
76.0
32.2
36
5
ACC51
NOMESCO Finland
Release of median nerve
339.9
32.2
32
*
N03AF02
ATC
oxcarbazepine; oral
7.6
31.3
46
65
N06AA09
ATC
amitriptyline; systemic
3.7
30.8
109
333
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.6
29.8
403
2528
R51.80
ICD-10 Finland
Headache
3.2
29.1
138
507
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.5
28.7
330
1906
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.5
28.1
281
1517
G530, B029,
ICD-10 Finland
+∞
27.3
26
*
B02.3
ICD-10 Finland
Zoster ocular disease
38.6
26.4
33
9
A02BC02
ATC
pantoprazole; systemic
2.8
25.9
497
3577
R53
ICD-10 Finland
Malaise and fatigue
2.4
22.8
230
1223
S01AD03
ATC
aciclovir; ophthalmic
5.0
22.6
51
110
J01DB01
ATC
cefalexin; oral
3.2
22.4
551
4304
M79.6
ICD-10 Finland
Pain in limb
2.3
22.2
320
1972
Z01.8
ICD-10 Finland
Other specified special examinations
2.5
22.2
177
845
M54.5
ICD-10 Finland
Low back pain
2.3
22.1
261
1480
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.3
21.6
281
1655
ACC59
NOMESCO Finland
Decompression and freeing of adhesions of peripheral nerve: other or unspecified
51.9
21.3
25
5
L04AX01
ATC
azathioprine; systemic
4.8
20.9
49
109
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
3.9
20.9
65
180
JN3AD
NOMESCO Finland
Abdominal CT examination
2.8
20.8
117
467
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.8
20.5
123
508
R06.0
ICD-10 Finland
Dyspnoea
2.3
20.4
236
1318
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
2.9
20.3
109
424
R51.81
ICD-10 Finland
Facial pain NOS
7.1
19.7
30
44
G63.0*B02.29
ICD-10 Finland
Postherpetic polyneuropathy
108.5
19.7
21
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.7
19.6
120
500
A02BC05
ATC
esomeprazole; systemic
2.2
19.5
293
1808
L28
ICPC
Limited function/disability (L)
2.3
19.3
185
951
R07.4
ICD-10 Finland
Chest pain, unspecified
2.2
19.3
232
1311
S01
ICPC
Pain/tenderness of skin
4.0
19.2
58
157
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.4
19.2
158
759
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
6.0
19.0
34
59
R52.2
ICD-10 Finland
Other chronic pain
4.8
18.7
43
94
R03AC02
ATC
salbutamol; inhalant
2.1
18.6
371
2534
R11
ICD-10 Finland
Nausea and vomiting
3.0
18.4
92
343
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.5
18.4
144
675
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
3.8
18.1
57
159
N02BE01
ATC
paracetamol; systemic, rectal
4.2
18.0
597
5053
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.7
17.9
107
439
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
2.1
17.8
283
1767
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.3
17.6
163
821
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
4.4
17.5
46
112
G50.1
ICD-10 Finland
Atypical facial pain
21.6
17.4
25
12
H04.10
ICD-10 Finland
Dry eye syndrome
2.8
17.4
100
402
R50.9
ICD-10 Finland
Fever, unspecified
2.5
17.4
130
595
AA1AD
NOMESCO Finland
CT of head and brain
2.1
17.2
254
1539
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.4
17.2
148
722
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
3.5
17.0
61
186
XW000
NOMESCO Finland
Bone marrow biopsy
4.0
17.0
50
133
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.1
16.9
235
1391
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.1
16.1
70
241
C03CA01
ATC
furosemide; systemic
2.0
15.5
289
1887
S18
ICPC
Laceration/cut
2.0
15.4
332
2274
H01
ICPC
Ear pain/earache
2.8
15.4
87
346
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
3.3
15.2
60
194
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.2
15.2
155
808
WZC00
NOMESCO Finland
Treatment plan or consultation
2.0
15.2
244
1509
H03.1*B02.3
ICD-10 Finland
Zoster blepharitis
24.1
15.2
21
9
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.0
15.2
330
2264
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
4.6
15.2
37
85
J45.9
ICD-10 Finland
Asthma, unspecified
2.2
14.8
153
802
L04AA06
ATC
mycophenolic acid; systemic
6.8
14.6
23
35
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.1
14.5
186
1057
N01
ICPC
Headache
2.7
14.5
83
332
XCW99
NOMESCO Finland
Other investigative procedure of eye
2.5
14.5
100
439
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
2.9
14.2
72
270
N06AA10
ATC
nortriptyline; systemic
6.6
14.2
23
36
A02BC01
ATC
omeprazole; systemic
2.0
14.1
206
1225
G530, B022,
ICD-10 Finland
+∞
13.6
13
*
R05
ICPC
Cough
2.0
13.5
181
1043
R52.0
ICD-10 Finland
Acute pain
4.4
13.3
34
81
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.1
13.3
142
751
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.6
13.2
83
348
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
3.2
13.1
53
174
R03AK06
ATC
salmeterol and fluticasone; inhalant
2.3
13.0
114
555
H22.0*B02.3
ICD-10 Finland
Zoster iridocyclitis
29.0
13.0
17
6
R05
ICD-10 Finland
Cough
2.1
13.0
155
854
M25.5
ICD-10 Finland
Pain in joint
1.9
13.0
208
1272
R02
ICPC
Shortness of breath/dyspnoea
2.2
13.0
119
591
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.9
12.8
219
1369
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
3.2
12.7
51
167
M03BX02
ATC
tizanidine; oral
1.8
12.7
359
2626
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.7
12.6
75
305
ZX120
NOMESCO Finland
Intravenous
2.5
12.6
83
355
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.8
12.5
319
2255
H62.1*B02.8
ICD-10 Finland
Otitis externa in zoster
132.5
12.5
13
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
2.4
12.5
91
409
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
2.0
12.1
176
1037
H02AB04
ATC
methylprednisolone; systemic
2.2
12.1
112
558
J01FA10
ATC
azithromycin; systemic
1.8
12.0
331
2387
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
4.2
12.0
32
79
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.8
12.0
249
1648
TDM10
NOMESCO Finland
Puncture of maxillary antrum
4.0
12.0
34
88
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
3.1
12.0
53
184
N03AE01
ATC
clonazepam; systemic
3.3
11.9
46
147
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
3.8
11.8
36
98
L03
ICPC
Low back symptom/complaint
1.9
11.8
187
1133
SPAT1263
SPAT
Sampling
1.8
11.7
277
1902
TAC00
NOMESCO Finland
Peripheral nerve block
30.7
11.7
15
5
G56.2
ICD-10 Finland
Lesion of ulnar nerve
19.4
11.6
17
9
Z71.8
ICD-10 Finland
Other specified counselling
1.9
11.6
224
1445
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.4
11.6
86
389
R03BA05
ATC
fluticasone; inhalant
2.1
11.6
123
646
R52.9
ICD-10 Finland
Pain, unspecified
2.4
11.5
83
371
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
2.6
11.4
68
277
K59.09
ICD-10 Finland
Constipation, unspecified
2.6
11.4
67
271
X59
ICD-10 Finland
Exposure to unspecified factor
2.1
11.4
129
694
G44.2
ICD-10 Finland
Tension-type headache
2.3
11.3
94
446
M70.6
ICD-10 Finland
Trochanteric bursitis
2.2
11.3
105
523
R06AE07
ATC
cetirizine; oral
1.8
11.3
265
1812
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.5
11.2
73
311
K80.0
ICD-10 Finland
Calculus of gallbladder with acute cholecystitis
3.4
11.1
40
122
R42
ICD-10 Finland
Dizziness and giddiness
1.9
11.1
186
1145
I50.9
ICD-10 Finland
Heart failure, unspecified
2.0
11.1
148
844
A07AA02
ATC
nystatin; oral
2.9
11.1
54
198
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.8
11.0
270
1868
M01AH05
ATC
etoricoxib; oral
1.8
10.9
363
2736
G55.1*M51.1
ICD-10 Finland
Compression of nerve roots and nerve plexus in disc diseases in the lumbar region and other regions
12.2
10.9
19
16
A99
ICPC
Disease/condition unspecnature/site
2.3
10.9
88
413
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
2.7
10.9
59
229
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.1
10.8
123
661
A04
ICPC
Weakness/tiredness general
2.0
10.8
130
713
H90.3
ICD-10 Finland
Sensorineural hearing loss, bilateral
1.9
10.8
156
913
M48.0
ICD-10 Finland
Spinal stenosis
2.2
10.8
98
483
L17
ICPC
Foot/toe symptom/complaint
1.8
10.7
209
1348
K57.3
ICD-10 Finland
Diverticular disease of large intestine without perforation or abscess
1.9
10.7
153
893
N05CF01
ATC
zopiclone; oral
1.8
10.6
235
1572
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.4
10.6
78
351
K08.80
ICD-10 Finland
Toothache NOS
2.8
10.6
55
209
UJF32
NOMESCO Finland
Coloscopy
1.8
10.5
190
1194
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
3.0
10.5
49
175
R07.3
ICD-10 Finland
Other chest pain
2.4
10.5
81
372
S29
ICPC
Skin symptom/complaint other
2.0
10.5
143
821
B02.2
ICD-10 Finland
Zoster with other nervous system involvement
111.8
10.4
11
*
M54.9
ICD-10 Finland
Dorsalgia, unspecified
2.3
10.4
85
401
A46
ICD-10 Finland
Erysipelas
2.0
10.4
120
649
M75.1
ICD-10 Finland
Rotator cuff syndrome
1.9
10.3
163
981
L04AX03
ATC
methotrexate; systemic
2.5
10.3
70
304
TQW99
NOMESCO Finland
Other minor procedure on skin
2.8
10.0
53
203
M54.4
ICD-10 Finland
Lumbago with sciatica
2.1
10.0
112
599
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
2.5
9.9
68
296
NA3EA
NOMESCO Finland
Lumbar spine X-ray examination with flexion
4.4
9.9
25
59
A03FA01
ATC
metoclopramide; systemic, rectal
1.9
9.9
162
985
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
3.3
9.9
38
121
A41.9
ICD-10 Finland
Sepsis, unspecified
3.3
9.9
37
116
D07AC01
ATC
betamethasone; topical
1.7
9.9
238
1625
SPAT1254
SPAT
Administration of medicine
2.0
9.8
117
639
N06AX11
ATC
mirtazapine; oral
1.8
9.8
227
1531
H57.1
ICD-10 Finland
Ocular pain
3.5
9.7
33
97
M01AB05
ATC
diclofenac; systemic, rectal
1.7
9.7
394
3095
J01MA12
ATC
levofloxacin; systemic
1.9
9.6
140
818
L04AA01
ATC
[U] ciclosporin
8.6
9.6
20
24
TAB00
NOMESCO Finland
Lumbar puncture
3.3
9.6
36
113
J01MA02
ATC
ciprofloxacin; systemic
1.7
9.5
269
1913
SAA03
NOMESCO Finland
Extended examination of mouth
1.8
9.5
214
1429
J02AC01
ATC
fluconazole; systemic
1.7
9.5
224
1516
H10.9
ICD-10 Finland
Conjunctivitis, unspecified
2.8
9.5
47
174
WX110
NOMESCO Finland
Infiltration anesthesia
1.7
9.4
414
3312
J01AA02
ATC
doxycycline; systemic
1.9
9.4
494
4158
N30.0
ICD-10 Finland
Acute cystitis
1.9
9.3
134
780
S22.3
ICD-10 Finland
Fracture of rib
2.5
9.3
60
254
Z02.7
ICD-10 Finland
Issue of medical certificate
2.6
9.3
57
236
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
2.4
9.2
64
280
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
2.1
9.2
95
492
Z76.0
ICD-10 Finland
Issue of repeat prescription
1.8
9.1
171
1082
SFA10
NOMESCO Finland
One-surface restoration
1.7
9.1
308
2291
M04AA01
ATC
allopurinol; systemic
2.0
9.1
109
596
H53.1
ICD-10 Finland
Subjective visual disturbances
2.6
9.0
52
208
D07AB02
ATC
hydrocortisone butyrate; topical
1.7
9.0
198
1309
WW200
NOMESCO Finland
Immunization
4.3
9.0
23
55
J45.1
ICD-10 Finland
Nonallergic asthma
2.5
8.9
57
240
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
2.6
8.8
51
205
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
2.4
8.7
61
268
L03AA02
ATC
filgrastim; parenteral
3.5
8.7
30
89
ZYC01
NOMESCO Finland
Remote contact by phone
2.7
8.7
46
176
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
2.3
8.7
65
295
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.2
8.6
73
349
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
1.7
8.6
201
1350
S19
ICPC
Skin injury other
3.0
8.6
38
132
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.4
8.6
58
251
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.3
8.6
71
336
R60.0
ICD-10 Finland
Localized oedema
2.0
8.5
102
556
J01FA06
ATC
roxithromycin; oral
1.7
8.5
251
1791
J01CA04
ATC
amoxicillin; systemic
1.8
8.5
486
4113
R01AD12
ATC
fluticasone furoate; nasal
1.8
8.5
164
1042
UDC00
NOMESCO Finland
Ear microscopy
2.4
8.5
58
252
H60.9
ICD-10 Finland
Otitis externa, unspecified
2.5
8.5
53
221
JN4AD
NOMESCO Finland
Body CT examination
2.1
8.5
90
470
A06AD11
ATC
lactulose; oral
1.9
8.4
126
742
P01BA02
ATC
hydroxychloroquine; oral
2.4
8.4
61
273
SPAT1216
SPAT
Assessment of functional ability
1.9
8.3
130
775
L50.0
ICD-10 Finland
Allergic urticaria
4.2
8.3
22
54
R23.3
ICD-10 Finland
Spontaneous ecchymoses
3.9
8.3
24
63
127
Kela drug reimbursment
Transplant complication
7.2
8.3
19
27
M54.1
ICD-10 Finland
Radiculopathy
3.4
8.3
29
87
L15
ICPC
Knee symptom/complaint
1.8
8.3
167
1074
N29
ICPC
Neurological sympt/complt other
4.3
8.3
21
50
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.1
8.2
35
119
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
3.7
8.2
26
73
H02AB09
ATC
hydrocortisone; systemic
4.5
8.2
20
46
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
2.3
8.2
64
296
L05
ICPC
Flank/axilla symptom/complaint
2.5
8.1
54
232
A06AC01
ATC
ispaghula (psylla seeds); oral
1.7
8.1
190
1275
WW500
NOMESCO Finland
Blood transfusion
2.9
8.0
38
137
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.7
8.0
189
1268
M79.1
ICD-10 Finland
Myalgia
2.0
8.0
95
516
J01FF01
ATC
clindamycin; systemic
1.7
8.0
169
1100
SPAT1215
SPAT
Assessment of need for medical rehabilitation
3.1
8.0
33
110
R07.0
ICD-10 Finland
Pain in throat
2.8
8.0
40
149
C08CA01
ATC
amlodipine; oral
1.6
8.0
284
2117
J01MA14
ATC
moxifloxacin; systemic
2.2
8.0
69
333
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
4.7
7.9
18
39
M50.3
ICD-10 Finland
Other cervical disc degeneration
4.7
7.9
18
39
L08
ICPC
Shoulder symptom/complaint
1.8
7.9
143
890
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
1.7
7.9
194
1315
A03
ICPC
Fever
2.0
7.9
93
504
TPH04
NOMESCO Finland
Cathetrisation of vein
1.8
7.9
149
940
J01FA09
ATC
clarithromycin; systemic
1.7
7.8
181
1208
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
4.3
7.8
20
48
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
3.3
7.8
29
91
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
1.8
7.7
140
871
L11
ICPC
Wrist symptom/complaint
2.3
7.7
58
263
B02.29
ICD-10 Finland
Herpes zoster polyneuropathy
45.5
7.7
9
*
SHA02
NOMESCO Finland
Stomatognathic treatment, basic
2.8
7.7
39
146
SAA02
NOMESCO Finland
Basic examination of mouth
1.6
7.7
359
2846
R03AL09
ATC
formoterol, glycopyrronium bromide and beclometasone; inhalant
3.1
7.7
31
102
M01AE02
ATC
naproxen; oral, rectal
1.6
7.7
327
2538
B00.9
ICD-10 Finland
Herpesviral infection, unspecified
18.6
7.6
11
6
SPAT1153
SPAT
Removal of sutures
1.7
7.6
204
1413
R03AK08
ATC
formoterol and beclometasone; inhalant
2.9
7.6
36
130
E0000UV, ,
ATC
1.6
7.6
260
1913
XQ800
NOMESCO Finland
Prick test
2.7
7.6
41
159
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
2.1
7.6
76
388
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.6
7.5
45
184
M23.9
ICD-10 Finland
Internal derangement of knee, unspecified
2.4
7.5
54
241
M03BC01
ATC
orphenadrine (citrate); systemic
1.8
7.5
122
736
Z01.2
ICD-10 Finland
Dental examination
1.6
7.4
252
1850
Z3231
NOMESCO Finland
Registered nurse
1.7
7.3
180
1217
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
2.6
7.3
42
168
R03BA01
ATC
beclometasone; inhalant
2.0
7.3
88
480
D01
ICPC
Abdominal pain/cramps general
2.0
7.3
79
415
GD1AD
NOMESCO Finland
Thorax CT examination
2.3
7.3
53
237
N01BX04
ATC
capsaicin; inhalant, oral, topical, transdermal
+∞
7.3
7
*
G530, B0229,
ICD-10 Finland
+∞
7.3
7
*
ACC53
NOMESCO Finland
Release of ulnar nerve
+∞
7.3
7
*
SPAT1229
SPAT
Assessment of need for aid
2.2
7.3
65
317
WYA05
NOMESCO Finland
Emergency visit or other similar visit involving procedures
1.6
7.3
250
1836
A02BC03
ATC
lansoprazole; oral
1.6
7.3
192
1322
D47.2
ICD-10 Finland
Monoclonal gammopathy of undetermined significance (MGUS)
4.4
7.3
18
42
R01AD09
ATC
mometasone; nasal
1.6
7.2
249
1829
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
2.6
7.2
41
163
C09CA06
ATC
candesartan; oral
1.7
7.2
155
1010
TNX00
NOMESCO Finland
Puncture and needle biopsy of soft tissue, unspecified region
4.6
7.2
17
38
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic
1.6
7.2
251
1851
B01.9
ICD-10 Finland
Varicella without complication
30.4
7.2
9
*
S20.2
ICD-10 Finland
Contusion of thorax
2.6
7.2
40
158
R04.0
ICD-10 Finland
Epistaxis
2.2
7.1
63
306
K81.0
ICD-10 Finland
Acute cholecystitis
3.8
7.1
21
56
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
4.1
7.1
19
47
XA402
NOMESCO Finland
ENMG
5.7
7.1
19
34
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
2.5
7.1
45
189
R03DC03
ATC
montelukast; oral
1.9
7.1
99
568
L30.9
ICD-10 Finland
Dermatitis, unspecified
1.8
7.1
128
795
R5140
NOMESCO Finland
Monitoring the use of the aid
2.0
7.1
74
384
K02.1
ICD-10 Finland
Caries of dentine
1.6
7.1
312
2424
B34.9
ICD-10 Finland
Viral infection, unspecified
4.3
7.1
18
43
W19
ICD-10 Finland
Unspecified fall
2.0
7.0
75
392
SAA01
NOMESCO Finland
Simple examination of mouth
1.6
7.0
393
3222
R01AD08
ATC
fluticasone; nasal
1.7
7.0
157
1035
L04AD01
ATC
ciclosporin; systemic
5.9
7.0
18
31
M43.1
ICD-10 Finland
Spondylolisthesis
3.0
6.9
30
103
J09
ICD-10 Finland
Influenza due to identified zoonotic or pandemic influenza virus
3.3
6.9
26
82
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
3.4
6.9
24
72
M01AE01
ATC
ibuprofen; systemic, rectal
1.8
6.9
524
4624
Z2446
NOMESCO Finland
Social worker
2.4
6.8
49
218
SPAT1301
SPAT
No procedures
1.6
6.8
207
1471
M05BA04
ATC
alendronic acid; oral
2.0
6.8
82
447
N03
ICPC
Pain face
11.1
6.8
12
11
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
11.1
6.8
12
11
M54.3
ICD-10 Finland
Sciatica
2.6
6.8
39
156
F32.00
ICD-10 Finland
Mild depressive episode without somatic syndrome
3.2
6.8
26
83
R21
ICPC
Throat symptom/complaint
1.8
6.8
103
607
R03BB04
ATC
tiotropium bromide; inhalant
2.0
6.8
77
412
T78.4
ICD-10 Finland
Allergy, unspecified
3.3
6.8
25
78
G55.2*M47.9
ICD-10 Finland
Nerve root and plexus compressions in spondylosis
16.9
6.8
10
6
NF1AA
NOMESCO Finland
Hip X-ray examination
2.0
6.8
76
405
C07AB07
ATC
bisoprolol; oral
1.5
6.7
348
2790
D07AD01
ATC
clobetasol; topical
1.8
6.7
108
647
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
1.9
6.7
82
450
XG410
NOMESCO Finland
Flow-volume spirometry
2.8
6.7
34
128
R03AK07
ATC
formoterol and budesonide; inhalant
1.8
6.7
119
736
ZXA10
NOMESCO Finland
Bilateral
1.7
6.6
140
907
EB1AA
NOMESCO Finland
Intraoral radiographic dental examination
1.5
6.6
295
2286
KMAK, ,
NOMESCO Finland
1.6
6.6
267
2024
A11
ICPC
Chest pain NOS
2.0
6.6
71
372
R4120
NOMESCO Finland
Occupational therapy
2.4
6.6
45
196
SPAT1255
SPAT
Intravenous administration of medicine
2.3
6.6
51
235
A98
ICPC
Health maint/preventive medicine
2.2
6.6
585
5367
-1, ,
NOMESCO Finland
1.6
6.5
176
1214
L13
ICPC
Hip symptom/complaint
1.7
6.5
134
862
A10AB05
ATC
insulin aspart; parenteral
2.2
6.5
52
243
SPAT1325
SPAT
Vaccination
1.6
6.5
230
1692
M10.9
ICD-10 Finland
Gout, unspecified
2.2
6.5
56
270
K30
ICD-10 Finland
Functional dyspepsia
2.0
6.5
71
375
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
1.8
6.5
105
631
WX109
NOMESCO Finland
Extensive surface anesthesy of skin with external ointment or geel
70.5
6.4
7
*
R01AD58
ATC
fluticasone, combinations; nasal
1.7
6.4
117
727
R4110
NOMESCO Finland
Physiotherapy
1.6
6.4
181
1262
Z01.6
ICD-10 Finland
Radiological examination, not elsewhere classified
2.0
6.4
67
348
M01AE03
ATC
ketoprofen; systemic, rectal
1.6
6.4
228
1679
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
3.2
6.4
25
81
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
1.7
6.4
122
769
R20.2
ICD-10 Finland
Paraesthesia of skin
2.5
6.4
41
174
R06AE09
ATC
levocetirizine; oral
1.9
6.3
79
436
M17.1
ICD-10 Finland
Other primary gonarthrosis
1.7
6.3
148
984
C01DA14
ATC
isosorbide mononitrate; oral
1.7
6.3
134
870
G50.8
ICD-10 Finland
Other disorders of trigeminal nerve
+∞
6.3
6
*
A29
ICPC
General symptom/complaint other
1.8
6.3
105
637
L12
ICPC
Hand/finger symptom/complaint
1.8
6.2
101
606
D09
ICPC
Nausea
2.7
6.2
33
127
K04.5
ICD-10 Finland
Chronic apical periodontitis
1.6
6.2
155
1047
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
1.9
6.2
83
469
H25.1
ICD-10 Finland
Senile nuclear cataract
1.5
6.2
244
1833
F01
ICPC
Eye pain
3.5
6.2
21
62
G04CA02
ATC
tamsulosin; oral
1.6
6.2
160
1091
L88
ICPC
Rheumatoid/seropositive arthritis
2.8
6.2
31
116
SPAT1222
SPAT
Counselling/guidance promoting independent living
1.7
6.2
117
735
P01AB01
ATC
metronidazole; oral, rectal
1.5
6.2
233
1735
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
2.5
6.2
38
158
M01AC01
ATC
piroxicam; systemic, rectal
1.9
6.1
87
501
R05DA20
ATC
opium alkaloids and derivatives - combinations
1.6
6.1
159
1085
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
2.4
6.1
43
190
XF404
NOMESCO Finland
Ambulatory ECG
2.0
6.1
67
354
R4110, ,
SPAT
1.8
6.1
90
525
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
3.7
6.1
19
53
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
2.4
6.1
41
178
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
2.6
6.1
33
129
R51
ICD-10 Finland
Headache
2.6
6.0
35
141
H15.1
ICD-10 Finland
Episcleritis
6.1
6.0
15
25
D11
ICPC
Diarrhoea
1.9
6.0
72
392
N05BB01
ATC
hydroxyzine; systemic
2.3
6.0
44
198

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
1.5e+00
2.7e+00
3.4e+00
1.0e+50
4.5e+00
4.2e+00
3.0e+00
cases:3.79%
controls:0.88%
cases:3.79%
controls:0.27%
cases:2.84%
controls:0.09%
cases:14.06%
controls:0.00%
cases:9.21%
controls:0.11%
cases:16.55%
controls:0.30%
cases:9.78%
controls:0.56%
24
56
609
6274
24
17
609
6313
18
6
615
6324
89
0
544
6330
58
7
572
6294
97
18
489
5948
40
24
369
4269
valaciclovir; oral
J05AB11 [21603137]
1.7e+00
3.2e+00
4.8e+00
1.0e+50
3.7e+00
2.7e+00
1.7e+00
cases:12.64%
controls:2.51%
cases:18.33%
controls:0.87%
cases:17.38%
controls:0.17%
cases:3.16%
controls:0.00%
cases:4.76%
controls:0.13%
cases:10.75%
controls:0.79%
cases:11.98%
controls:2.42%
80
159
553
6171
116
55
517
6275
110
11
523
6319
20
0
613
6330
30
8
600
6293
63
47
523
5919
49
104
360
4189
aciclovir; oral, parenteral
J05AB01 [21603131]
1.5e+00
3.5e+00
5.0e+00
1.0e+50
3.5e+00
1.9e+00
1.4e+00
cases:12.64%
controls:2.99%
cases:23.54%
controls:0.92%
cases:17.85%
controls:0.14%
cases:1.90%
controls:0.00%
cases:5.24%
controls:0.16%
cases:7.51%
controls:1.21%
cases:10.02%
controls:2.77%
80
189
553
6141
149
58
484
6272
113
9
520
6321
12
0
621
6330
33
10
597
6291
44
72
542
5894
41
119
368
4174
gabapentin; oral
N02BF01 [955005]
1.5e+00
2.7e+00
3.6e+00
—
3.6e+00
3.0e+00
2.1e+00
cases:13.11%
controls:3.35%
cases:21.48%
controls:1.82%
cases:15.01%
controls:0.49%
—
—
cases:20.79%
controls:0.71%
cases:28.16%
controls:1.86%
cases:25.18%
controls:4.12%
83
212
550
6118
136
115
497
6215
95
31
538
6299
—
131
45
499
6256
165
111
421
5855
103
177
306
4116
pregabalin; oral
N02BF02 [955152]
1.3e+00
2.4e+00
3.2e+00
—
3.5e+00
2.6e+00
2.2e+00
cases:16.27%
controls:4.91%
cases:21.96%
controls:2.42%
cases:18.96%
controls:0.90%
—
—
cases:21.11%
controls:0.79%
cases:24.91%
controls:2.30%
cases:26.89%
controls:4.05%
103
311
530
6019
139
153
494
6177
120
57
513
6273
—
133
50
497
6251
146
137
440
5829
110
174
299
4119
nortriptyline; oral, parenteral
N06AA10 [21604697]
1.3e+00
2.8e+00
2.4e+00
1.0e+50
3.8e+00
2.6e+00
2.0e+00
cases:3.16%
controls:0.85%
cases:3.79%
controls:0.24%
cases:1.58%
controls:0.14%
cases:1.11%
controls:0.00%
cases:3.33%
controls:0.08%
cases:4.44%
controls:0.35%
cases:4.89%
controls:0.68%
20
54
613
6276
24
15
609
6315
10
9
623
6321
7
0
626
6330
21
5
609
6296
26
21
560
5945
20
29
389
4264
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
2.1e+00
2.2e+00
2.8e+00
—
2.5e+00
2.6e+00
1.3e+00
cases:5.53%
controls:0.68%
cases:3.32%
controls:0.36%
cases:1.26%
controls:0.08%
—
—
cases:0.95%
controls:0.08%
cases:3.58%
controls:0.28%
cases:3.18%
controls:0.91%
35
43
598
6287
21
23
612
6307
8
5
625
6325
—
6
5
624
6296
21
17
565
5949
13
39
396
4254
carbamazepine; oral, rectal
N03AF01 [21604417]
1.5e+00
2.4e+00
2.6e+00
—
2.8e+00
2.2e+00
1.8e+00
cases:2.21%
controls:0.49%
cases:3.16%
controls:0.30%
cases:1.74%
controls:0.13%
—
—
cases:1.59%
controls:0.10%
cases:3.24%
controls:0.37%
cases:2.93%
controls:0.49%
14
31
619
6299
20
19
613
6311
11
8
622
6322
—
10
6
620
6295
19
22
567
5944
12
21
397
4272
General Practice
1 [38004446]
7.0e-01
9.4e-01
2.0e+00
5.6e+00
1.6e+00
8.6e-01
7.1e-01
cases:32.86%
controls:19.53%
cases:19.59%
controls:8.69%
cases:7.90%
controls:1.15%
cases:17.38%
controls:0.08%
cases:8.10%
controls:1.67%
cases:20.14%
controls:9.62%
cases:39.85%
controls:24.55%
208
1236
425
5094
124
550
509
5780
50
73
583
6257
110
5
523
6325
51
105
579
6196
118
574
468
5392
163
1054
246
3239
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
1.3e+00
2.0e+00
3.0e+00
—
3.0e+00
1.9e+00
1.1e+00
cases:22.75%
controls:7.44%
cases:18.17%
controls:2.78%
cases:8.85%
controls:0.47%
—
—
cases:8.89%
controls:0.51%
cases:13.99%
controls:2.38%
cases:17.11%
controls:6.55%
144
471
489
5859
115
176
518
6154
56
30
577
6300
—
56
32
574
6269
82
142
504
5824
70
281
339
4012
amitriptyline; oral, parenteral
N06AA09 [21604696]
1.4e+00
2.2e+00
2.6e+00
—
3.0e+00
2.0e+00
1.2e+00
cases:15.32%
controls:4.42%
cases:16.27%
controls:2.21%
cases:7.58%
controls:0.63%
—
—
cases:9.05%
controls:0.51%
cases:13.82%
controls:2.13%
cases:13.20%
controls:4.47%
97
280
536
6050
103
140
530
6190
48
40
585
6290
—
57
32
573
6269
81
127
505
5839
54
192
355
4101
Inpatient Hospital
21 [8717]
7.4e-01
9.7e-01
1.7e+00
5.3e+00
1.8e+00
9.1e-01
6.2e-01
cases:51.34%
controls:33.52%
cases:24.33%
controls:10.84%
cases:8.37%
controls:1.60%
cases:14.06%
controls:0.08%
cases:9.37%
controls:1.70%
cases:22.01%
controls:10.21%
cases:35.45%
controls:22.85%
325
2122
308
4208
154
686
479
5644
53
101
580
6229
89
5
544
6325
59
107
571
6194
129
609
457
5357
145
981
264
3312
Internal Medicine
11 [38004456]
7.6e-01
1.2e+00
1.8e+00
4.7e+00
1.8e+00
9.8e-01
6.4e-01
cases:42.97%
controls:26.13%
cases:25.28%
controls:9.43%
cases:8.21%
controls:1.42%
cases:7.90%
controls:0.08%
cases:8.25%
controls:1.52%
cases:22.70%
controls:9.89%
cases:37.16%
controls:23.85%
272
1654
361
4676
160
597
473
5733
52
90
581
6240
50
5
583
6325
52
96
578
6205
133
590
453
5376
152
1024
257
3269
duloxetine; oral
N06AX21 [21604749]
1.2e+00
1.5e+00
1.8e+00
1.0e+50
2.5e+00
2.3e+00
2.1e+00
cases:5.21%
controls:1.69%
cases:4.42%
controls:1.06%
cases:2.21%
controls:0.38%
cases:1.58%
controls:0.00%
cases:3.97%
controls:0.35%
cases:9.04%
controls:0.99%
cases:11.98%
controls:1.70%
33
107
600
6223
28
67
605
6263
14
24
619
6306
10
0
623
6330
25
22
605
6279
53
59
533
5907
49
73
360
4220
Outpatient Visit
OP [9202]
1.1e+00
9.9e-01
8.8e-01
4.4e+00
1.2e+00
1.1e+00
9.5e-01
cases:93.84%
controls:83.32%
cases:83.10%
controls:64.66%
cases:25.28%
controls:12.29%
cases:26.70%
controls:0.44%
cases:30.63%
controls:12.20%
cases:82.08%
controls:61.50%
cases:94.38%
controls:86.70%
594
5274
39
1056
526
4093
107
2237
160
778
473
5552
169
28
464
6302
193
769
437
5532
481
3669
105
2297
386
3722
23
571
oxycodone; oral, parenteral
N02AA05 [21604260]
1.3e+00
1.6e+00
2.2e+00
—
2.7e+00
1.6e+00
9.9e-01
cases:8.53%
controls:2.40%
cases:6.79%
controls:1.48%
cases:4.90%
controls:0.57%
—
—
cases:6.03%
controls:0.41%
cases:9.73%
controls:2.03%
cases:11.74%
controls:4.73%
54
152
579
6178
43
94
590
6236
31
36
602
6294
—
38
26
592
6275
57
121
529
5845
48
203
361
4090
Zoster without complication
B02.9 [45581143]
2.2e+00
4.2e+00
—
—
—
2.9e+00
1.1e+00
cases:9.16%
controls:1.15%
cases:17.06%
controls:0.30%
—
—
—
—
—
—
cases:4.78%
controls:0.28%
cases:3.42%
controls:1.12%
58
73
575
6257
108
19
525
6311
—
—
—
28
17
558
5949
14
48
395
4245
Zoster [herpes zoster]
B02 [45552205]
1.7e+00
4.0e+00
1.0e+50
1.0e+50
—
2.9e+00
1.6e+00
cases:3.48%
controls:0.66%
cases:7.42%
controls:0.14%
cases:5.85%
controls:0.00%
cases:0.95%
controls:0.00%
—
—
cases:2.56%
controls:0.15%
cases:3.18%
controls:0.63%
22
42
611
6288
47
9
586
6321
37
0
596
6330
6
0
627
6330
—
15
9
571
5957
13
27
396
4266
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
4.3e-01
8.9e-01
1.7e+00
3.9e+00
1.6e+00
8.8e-01
6.3e-01
cases:53.40%
controls:42.59%
cases:48.34%
controls:27.80%
cases:24.49%
controls:5.64%
cases:15.96%
controls:0.39%
cases:22.70%
controls:5.36%
cases:48.63%
controls:28.13%
cases:68.46%
controls:53.72%
338
2696
295
3634
306
1760
327
4570
155
357
478
5973
101
25
532
6305
143
338
487
5963
285
1678
301
4288
280
2306
129
1987
Hematology
82 [38004501]
1.6e+00
1.6e+00
2.0e+00
—
1.7e+00
1.5e+00
1.5e+00
cases:6.00%
controls:1.33%
cases:5.69%
controls:1.17%
cases:3.16%
controls:0.43%
—
—
cases:2.06%
controls:0.40%
cases:5.46%
controls:1.26%
cases:7.33%
controls:1.72%
38
84
595
6246
36
74
597
6256
20
27
613
6303
—
13
25
617
6276
32
75
554
5891
30
74
379
4219
Infectious Disease
44 [38004484]
1.2e+00
1.4e+00
2.0e+00
1.0e+50
1.9e+00
2.0e+00
1.3e+00
cases:6.95%
controls:2.20%
cases:3.00%
controls:0.77%
cases:0.95%
controls:0.13%
cases:0.95%
controls:0.00%
cases:1.27%
controls:0.19%
cases:4.95%
controls:0.72%
cases:7.09%
controls:2.00%
44
139
589
6191
19
49
614
6281
6
8
627
6322
6
0
627
6330
8
12
622
6289
29
43
557
5923
29
86
380
4207
Chronic lymphocytic leukaemia of B-cell type
C91.1 [45600564]
1.7e+00
1.7e+00
—
—
2.5e+00
2.0e+00
1.8e+00
cases:1.42%
controls:0.25%
cases:1.26%
controls:0.24%
—
—
—
—
cases:1.11%
controls:0.10%
cases:1.88%
controls:0.25%
cases:2.44%
controls:0.40%
9
16
624
6314
8
15
625
6315
—
—
7
6
623
6295
11
15
575
5951
10
17
399
4276
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
6.0e-01
9.7e-01
1.5e+00
3.4e+00
1.6e+00
7.7e-01
8.7e-01
cases:27.01%
controls:16.95%
cases:20.54%
controls:8.96%
cases:7.11%
controls:1.67%
cases:2.69%
controls:0.09%
cases:8.10%
controls:1.70%
cases:18.09%
controls:9.25%
cases:38.88%
controls:20.99%
171
1073
462
5257
130
567
503
5763
45
106
588
6224
17
6
616
6324
51
107
579
6194
106
552
480
5414
159
901
250
3392
Ophthalmology
18 [38004463]
5.8e-01
7.5e-01
1.6e+00
3.8e+00
1.1e+00
7.2e-01
7.9e-01
cases:35.86%
controls:23.87%
cases:19.59%
controls:10.32%
cases:9.16%
controls:2.02%
cases:3.95%
controls:0.09%
cases:6.03%
controls:2.02%
cases:18.60%
controls:10.01%
cases:40.59%
controls:23.67%
227
1511
406
4819
124
653
509
5677
58
128
575
6202
25
6
608
6324
38
127
592
6174
109
597
477
5369
166
1016
243
3277
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
1.6e+00
1.9e+00
—
—
2.9e+00
1.8e+00
1.0e+00
cases:7.90%
controls:1.69%
cases:5.21%
controls:0.84%
—
—
—
—
cases:2.06%
controls:0.11%
cases:5.29%
controls:0.91%
cases:5.38%
controls:1.96%
50
107
583
6223
33
53
600
6277
—
—
13
7
617
6294
31
54
555
5912
22
84
387
4209
Herpes zoster
S70 [2002001034]
1.7e+00
4.5e+00
1.0e+50
—
1.0e+50
3.0e+00
1.4e+00
cases:2.37%
controls:0.43%
cases:6.48%
controls:0.08%
cases:5.37%
controls:0.00%
—
—
cases:1.90%
controls:0.00%
cases:2.22%
controls:0.12%
cases:1.96%
controls:0.49%
15
27
618
6303
41
5
592
6325
34
0
599
6330
—
12
0
618
6301
13
7
573
5959
8
21
401
4272
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
4.6e-01
9.2e-01
1.4e+00
3.1e+00
1.6e+00
8.7e-01
7.2e-01
cases:41.07%
controls:30.60%
cases:35.55%
controls:18.01%
cases:11.85%
controls:3.27%
cases:3.16%
controls:0.14%
cases:14.60%
controls:3.32%
cases:33.96%
controls:17.78%
cases:54.77%
controls:37.18%
260
1937
373
4393
225
1140
408
5190
75
207
558
6123
20
9
613
6321
92
209
538
6092
199
1061
387
4905
224
1596
185
2697
lidocaine
C05AD01 [21601618]
1.8e+00
2.8e+00
—
—
—
2.9e+00
1.5e+00
cases:2.37%
controls:0.41%
cases:3.79%
controls:0.24%
—
—
—
—
—
—
cases:3.24%
controls:0.18%
cases:4.16%
controls:0.93%
15
26
618
6304
24
15
609
6315
—
—
—
19
11
567
5955
17
40
392
4253
lidocaine; ointment
D04AB01 [21602020]
1.8e+00
2.8e+00
—
—
—
2.9e+00
1.5e+00
cases:2.37%
controls:0.41%
cases:3.63%
controls:0.24%
—
—
—
—
—
—
cases:3.24%
controls:0.18%
cases:4.16%
controls:0.93%
15
26
618
6304
23
15
610
6315
—
—
—
19
11
567
5955
17
40
392
4253
Rheumatology
66 [38004491]
1.0e+00
1.5e+00
1.7e+00
—
2.1e+00
1.4e+00
1.2e+00
cases:9.95%
controls:3.79%
cases:9.00%
controls:2.12%
cases:2.37%
controls:0.43%
—
—
cases:2.06%
controls:0.27%
cases:7.51%
controls:2.04%
cases:11.00%
controls:3.59%
63
240
570
6090
57
134
576
6196
15
27
618
6303
—
13
17
617
6284
44
122
542
5844
45
154
364
4139
Bacteria identified in Sputum by Culture
6460-0 [3023419]
1.6e+00
2.7e+00
—
—
—
2.0e+00
2.3e+00
cases:1.58%
controls:0.32%
cases:1.90%
controls:0.13%
—
—
—
—
—
—
cases:1.37%
controls:0.18%
cases:2.44%
controls:0.26%
10
20
623
6310
12
8
621
6322
—
—
—
8
11
578
5955
10
11
399
4282
Pain general/multiple sites
A01 [2002000142]
8.1e-01
1.5e+00
2.2e+00
—
2.2e+00
1.6e+00
1.1e+00
cases:3.32%
controls:1.50%
cases:3.32%
controls:0.73%
cases:2.53%
controls:0.30%
—
—
cases:1.11%
controls:0.13%
cases:3.92%
controls:0.80%
cases:7.33%
controls:2.52%
21
95
612
6235
21
46
612
6284
16
19
617
6311
—
7
8
623
6293
23
48
563
5918
30
108
379
4185
codeine and paracetamol
N02AJ06 [1123647]
9.0e-01
1.3e+00
2.5e+00
—
2.1e+00
1.0e+00
8.2e-01
cases:33.18%
controls:16.81%
cases:20.38%
controls:6.35%
cases:11.22%
controls:1.04%
—
—
cases:6.98%
controls:0.95%
cases:14.33%
controls:5.68%
cases:29.34%
controls:15.42%
210
1064
423
5266
129
402
504
5928
71
66
562
6264
—
44
60
586
6241
84
339
502
5627
120
662
289
3631
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
5.6e-01
9.8e-01
1.2e+00
2.9e+00
1.5e+00
7.7e-01
7.4e-01
cases:30.33%
controls:19.89%
cases:27.01%
controls:12.16%
cases:8.06%
controls:2.56%
cases:1.90%
controls:0.11%
cases:9.84%
controls:2.49%
cases:23.21%
controls:12.24%
cases:39.12%
controls:23.55%
192
1259
441
5071
171
770
462
5560
51
162
582
6168
12
7
621
6323
62
157
568
6144
136
730
450
5236
160
1011
249
3282
Pharmacy visit
OMOP4822462 [581458]
1.2e+00
1.5e+00
1.6e+00
2.7e+00
1.5e+00
1.2e+00
2.1e+00
cases:99.21%
controls:97.42%
cases:98.26%
controls:92.39%
cases:88.94%
controls:60.73%
cases:33.65%
controls:3.35%
cases:87.46%
controls:61.18%
cases:97.61%
controls:92.66%
cases:99.76%
controls:98.09%
628
6167
5
163
622
5848
11
482
563
3844
70
2486
213
212
420
6118
551
3855
79
2446
572
5528
14
438
408
4211
1
82
Postzoster neuralgia
G53.0 [45547747]
3.8e+00
—
1.0e+50
1.0e+50
1.0e+50
—
4.7e+00
cases:4.90%
controls:0.11%
—
—
cases:4.42%
controls:0.00%
cases:29.07%
controls:0.00%
cases:10.00%
controls:0.00%
—
—
cases:11.25%
controls:0.12%
31
7
602
6323
—
28
0
605
6330
184
0
449
6330
63
0
567
6301
—
46
5
363
4288
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
4.7e-01
1.3e+00
2.2e+00
—
2.3e+00
1.5e+00
1.2e+00
cases:3.48%
controls:2.20%
cases:2.84%
controls:0.79%
cases:1.11%
controls:0.13%
—
—
cases:1.90%
controls:0.19%
cases:3.75%
controls:0.87%
cases:7.09%
controls:2.19%
22
139
611
6191
18
50
615
6280
7
8
626
6322
—
12
12
618
6289
22
52
564
5914
29
94
380
4199
oxycodone and naloxone; oral
N02AA55 [21604265]
1.1e+00
1.5e+00
2.3e+00
—
2.6e+00
1.0e+00
6.3e-01
cases:7.90%
controls:2.83%
cases:4.11%
controls:0.95%
cases:2.37%
controls:0.24%
—
—
cases:3.97%
controls:0.32%
cases:4.10%
controls:1.51%
cases:8.07%
controls:4.45%
50
179
583
6151
26
60
607
6270
15
15
618
6315
—
25
20
605
6281
24
90
562
5876
33
191
376
4102
Neurology
13 [38004458]
7.2e-01
1.1e+00
1.8e+00
—
2.4e+00
1.7e+00
8.5e-01
cases:23.06%
controls:12.76%
cases:12.95%
controls:4.90%
cases:4.58%
controls:0.82%
—
—
cases:7.78%
controls:0.78%
cases:20.99%
controls:4.66%
cases:23.96%
controls:11.88%
146
808
487
5522
82
310
551
6020
29
52
604
6278
—
49
49
581
6252
123
278
463
5688
98
510
311
3783
Carpal tunnel syndrome
G56.0 [45566891]
3.6e+00
2.5e+00
—
—
—
—
2.2e+00
cases:3.32%
controls:0.09%
cases:1.11%
controls:0.09%
—
—
—
—
—
—
—
—
cases:2.44%
controls:0.28%
21
6
612
6324
7
6
626
6324
—
—
—
—
10
12
399
4281
INR in Blood by Coagulation assay
34714-6 [3032080]
5.5e-01
6.9e-01
1.0e+00
3.6e+00
8.2e-01
8.0e-01
5.4e-01
cases:27.17%
controls:17.73%
cases:18.64%
controls:10.32%
cases:9.64%
controls:3.62%
cases:5.69%
controls:0.16%
cases:7.94%
controls:3.67%
cases:20.31%
controls:10.26%
cases:31.78%
controls:21.43%
172
1122
461
5208
118
653
515
5677
61
229
572
6101
36
10
597
6320
50
231
580
6070
119
612
467
5354
130
920
279
3373
Emergency Room Visit
ER [9203]
9.0e-01
1.2e+00
2.3e+00
—
1.9e+00
1.0e+00
6.9e-01
cases:59.40%
controls:37.39%
cases:33.33%
controls:12.91%
cases:14.06%
controls:1.55%
—
—
cases:11.11%
controls:1.87%
cases:27.47%
controls:12.17%
cases:48.66%
controls:32.29%
376
2367
257
3963
211
817
422
5513
89
98
544
6232
—
70
118
560
6183
161
726
425
5240
199
1386
210
2907
Office Visit
OMOP4822458 [581477]
1.0e+00
1.2e+00
2.2e+00
1.0e+50
1.8e+00
9.4e-01
8.4e-01
cases:20.38%
controls:8.61%
cases:6.64%
controls:2.04%
cases:2.37%
controls:0.27%
cases:1.42%
controls:0.00%
cases:1.90%
controls:0.32%
cases:4.95%
controls:1.99%
cases:12.47%
controls:5.80%
129
545
504
5785
42
129
591
6201
15
17
618
6313
9
0
624
6330
12
20
618
6281
29
119
557
5847
51
249
358
4044
Complement C3 [Mass/volume] in Serum or Plasma
4485-9 [3000620]
1.7e+00
2.2e+00
—
—
—
2.2e+00
1.7e+00
cases:3.16%
controls:0.57%
cases:2.05%
controls:0.22%
—
—
—
—
—
—
cases:1.54%
controls:0.17%
cases:3.91%
controls:0.75%
20
36
613
6294
13
14
620
6316
—
—
—
9
10
577
5956
16
32
393
4261
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
1.7e+00
2.2e+00
—
—
—
2.2e+00
1.7e+00
cases:3.00%
controls:0.55%
cases:2.05%
controls:0.22%
—
—
—
—
—
—
cases:1.54%
controls:0.17%
cases:3.91%
controls:0.75%
19
35
614
6295
13
14
620
6316
—
—
—
9
10
577
5956
16
32
393
4261
Thorax X-ray examination
GD1AA [2001303617]
8.8e-01
1.3e+00
1.8e+00
—
1.7e+00
1.2e+00
9.3e-01
cases:26.54%
controls:13.02%
cases:15.96%
controls:5.06%
cases:3.79%
controls:0.66%
—
—
cases:3.33%
controls:0.63%
cases:14.16%
controls:4.53%
cases:29.34%
controls:14.12%
168
824
465
5506
101
320
532
6010
24
42
609
6288
—
21
40
609
6261
83
270
503
5696
120
606
289
3687
Otolaryngology
4 [38004449]
8.5e-01
9.0e-01
1.9e+00
—
2.1e+00
1.3e+00
8.0e-01
cases:27.01%
controls:13.71%
cases:12.01%
controls:5.24%
cases:4.74%
controls:0.74%
—
—
cases:6.35%
controls:0.84%
cases:15.19%
controls:4.84%
cases:24.94%
controls:13.02%
171
868
462
5462
76
332
557
5998
30
47
603
6283
—
40
53
590
6248
89
289
497
5677
102
559
307
3734
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
6.7e-01
8.8e-01
1.2e+00
2.1e+00
1.1e+00
9.2e-01
8.4e-01
cases:63.03%
controls:46.54%
cases:48.34%
controls:28.03%
cases:18.01%
controls:6.07%
cases:2.05%
controls:0.27%
cases:16.67%
controls:6.08%
cases:50.34%
controls:28.73%
cases:71.15%
controls:51.55%
399
2946
234
3384
306
1774
327
4556
114
384
519
5946
13
17
620
6313
105
383
525
5918
295
1714
291
4252
291
2213
118
2080
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
7.0e-01
1.1e+00
1.8e+00
—
1.6e+00
1.5e+00
1.0e+00
cases:6.48%
controls:3.33%
cases:6.32%
controls:2.13%
cases:3.48%
controls:0.57%
—
—
cases:4.13%
controls:0.89%
cases:9.22%
controls:2.30%
cases:13.45%
controls:5.40%
41
211
592
6119
40
135
593
6195
22
36
611
6294
—
26
56
604
6245
54
137
532
5829
55
232
354
4061
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
9.8e-01
9.9e-01
2.3e+00
—
1.7e+00
1.2e+00
6.0e-01
cases:9.00%
controls:3.59%
cases:5.37%
controls:2.07%
cases:2.21%
controls:0.24%
—
—
cases:1.90%
controls:0.37%
cases:8.02%
controls:2.67%
cases:13.45%
controls:7.87%
57
227
576
6103
34
131
599
6199
14
15
619
6315
—
12
23
618
6278
47
159
539
5807
55
338
354
3955
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
1.2e+00
1.3e+00
1.5e+00
—
1.7e+00
1.1e+00
8.6e-01
cases:9.16%
controls:2.92%
cases:6.32%
controls:1.72%
cases:1.74%
controls:0.39%
—
—
cases:1.90%
controls:0.37%
cases:5.63%
controls:2.03%
cases:10.27%
controls:4.64%
58
185
575
6145
40
109
593
6221
11
25
622
6305
—
12
23
618
6278
33
121
553
5845
42
199
367
4094
Bacteria identified in Blood by Culture
600-7 [3023368]
6.7e-01
1.2e+00
2.2e+00
1.0e+50
1.7e+00
9.7e-01
7.5e-01
cases:14.06%
controls:7.69%
cases:10.90%
controls:3.46%
cases:3.95%
controls:0.44%
cases:1.58%
controls:0.00%
cases:3.02%
controls:0.54%
cases:10.07%
controls:4.06%
cases:21.52%
controls:11.48%
89
487
544
5843
69
219
564
6111
25
28
608
6302
10
0
623
6330
19
34
611
6267
59
242
527
5724
88
493
321
3800
Pain/tenderness of skin
S01 [2002000966]
1.3e+00
2.3e+00
—
—
—
2.2e+00
1.6e+00
cases:1.74%
controls:0.46%
cases:1.74%
controls:0.17%
—
—
—
—
—
—
cases:1.54%
controls:0.17%
cases:3.18%
controls:0.65%
11
29
622
6301
11
11
622
6319
—
—
—
9
10
577
5956
13
28
396
4265
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
1.9e-01
5.3e-01
1.3e+00
3.7e+00
1.3e+00
5.7e-01
3.6e-01
cases:56.24%
controls:51.52%
cases:54.34%
controls:41.30%
cases:24.33%
controls:7.91%
cases:16.27%
controls:0.47%
cases:24.76%
controls:7.98%
cases:57.00%
controls:42.91%
cases:72.62%
controls:64.87%
356
3261
277
3069
344
2614
289
3716
154
501
479
5829
103
30
530
6300
156
503
474
5798
334
2560
252
3406
297
2785
112
1508
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.9e-01
5.3e-01
1.3e+00
3.7e+00
1.3e+00
5.8e-01
3.5e-01
cases:56.56%
controls:51.86%
cases:54.82%
controls:41.66%
cases:24.49%
controls:8.07%
cases:16.27%
controls:0.47%
cases:24.92%
controls:8.16%
cases:57.85%
controls:43.41%
cases:72.86%
controls:65.36%
358
3283
275
3047
347
2637
286
3693
155
511
478
5819
103
30
530
6300
157
514
473
5787
339
2590
247
3376
298
2806
111
1487
Pneumonia, unspecified
J18.9 [45601123]
8.5e-01
1.1e+00
2.0e+00
—
1.4e+00
1.2e+00
7.7e-01
cases:9.79%
controls:4.45%
cases:6.00%
controls:2.07%
cases:1.11%
controls:0.16%
—
—
cases:1.59%
controls:0.38%
cases:7.00%
controls:2.23%
cases:14.43%
controls:7.22%
62
282
571
6048
38
131
595
6199
7
10
626
6320
—
10
24
620
6277
41
133
545
5833
59
310
350
3983
prednisolone; oral, parenteral
H02AB06 [21602734]
1.2e+00
1.4e+00
1.4e+00
1.0e+50
9.9e-01
1.2e+00
1.1e+00
cases:33.18%
controls:13.35%
cases:21.17%
controls:6.40%
cases:6.64%
controls:1.64%
cases:0.95%
controls:0.00%
cases:3.97%
controls:1.51%
cases:18.94%
controls:6.81%
cases:32.27%
controls:13.32%
210
845
423
5485
134
405
499
5925
42
104
591
6226
6
0
627
6330
25
95
605
6206
111
406
475
5560
132
572
277
3721
aciclovir
S01AD03 [21603588]
2.2e+00
—
1.0e+50
—
—
2.3e+00
2.8e+00
cases:1.90%
controls:0.22%
—
—
cases:2.84%
controls:0.00%
—
—
—
—
cases:1.02%
controls:0.10%
cases:2.20%
controls:0.14%
12
14
621
6316
—
18
0
615
6330
—
—
6
6
580
5960
9
6
400
4287
pantoprazole; oral, parenteral
A02BC02 [21600097]
8.1e-01
9.3e-01
9.8e-01
1.9e+00
8.4e-01
1.0e+00
7.6e-01
cases:40.44%
controls:23.29%
cases:30.49%
controls:14.74%
cases:9.95%
controls:3.98%
cases:1.26%
controls:0.19%
cases:8.57%
controls:3.89%
cases:32.76%
controls:14.77%
cases:42.05%
controls:25.37%
256
1474
377
4856
193
933
440
5397
63
252
570
6078
8
12
625
6318
54
245
576
6056
192
881
394
5085
172
1089
237
3204
oxcarbazepine; oral
N03AF02 [21604418]
1.4e+00
1.7e+00
2.0e+00
—
2.2e+00
2.0e+00
1.3e+00
cases:1.90%
controls:0.49%
cases:2.21%
controls:0.41%
cases:0.79%
controls:0.11%
—
—
cases:1.11%
controls:0.13%
cases:2.39%
controls:0.34%
cases:1.71%
controls:0.47%
12
31
621
6299
14
26
619
6304
5
7
628
6323
—
7
8
623
6293
14
20
572
5946
7
20
402
4273
prednisolone
A07EA01 [21600653]
1.2e+00
1.4e+00
1.4e+00
1.0e+50
9.8e-01
1.2e+00
1.1e+00
cases:33.18%
controls:13.48%
cases:21.17%
controls:6.41%
cases:6.64%
controls:1.66%
cases:0.95%
controls:0.00%
cases:3.97%
controls:1.52%
cases:18.94%
controls:6.84%
cases:32.27%
controls:13.42%
210
853
423
5477
134
406
499
5924
42
105
591
6225
6
0
627
6330
25
96
605
6205
111
408
475
5558
132
576
277
3717
Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
38917-1 [3042194]
1.8e+00
1.8e+00
—
—
—
2.0e+00
1.6e+00
cases:2.84%
controls:0.51%
cases:1.26%
controls:0.21%
—
—
—
—
—
—
cases:1.54%
controls:0.22%
cases:2.44%
controls:0.49%
18
32
615
6298
8
13
625
6317
—
—
—
9
13
577
5953
10
21
399
4272
Nephrology
39 [38004479]
1.3e+00
1.4e+00
1.7e+00
—
1.5e+00
1.1e+00
8.7e-01
cases:4.27%
controls:1.22%
cases:4.27%
controls:1.04%
cases:2.21%
controls:0.39%
—
—
cases:1.75%
controls:0.38%
cases:3.41%
controls:1.12%
cases:3.42%
controls:1.47%
27
77
606
6253
27
66
606
6264
14
25
619
6305
—
11
24
619
6277
20
67
566
5899
14
63
395
4230
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.9e-01
5.1e-01
1.2e+00
3.6e+00
1.3e+00
5.4e-01
3.3e-01
cases:58.77%
controls:54.15%
cases:58.77%
controls:46.00%
cases:26.86%
controls:9.72%
cases:16.27%
controls:0.55%
cases:28.41%
controls:9.86%
cases:60.92%
controls:47.49%
cases:75.31%
controls:68.65%
372
3428
261
2902
372
2912
261
3418
170
615
463
5715
103
35
530
6295
179
621
451
5680
357
2833
229
3133
308
2947
101
1346
Essential (primary) hypertension
I10 [45591453]
3.1e-01
4.7e-01
9.0e-01
4.0e+00
1.0e+00
4.2e-01
2.7e-01
cases:38.55%
controls:31.60%
cases:23.38%
controls:16.08%
cases:6.64%
controls:2.81%
cases:8.85%
controls:0.17%
cases:7.14%
controls:2.75%
cases:23.38%
controls:16.66%
cases:41.81%
controls:35.38%
244
2000
389
4330
148
1018
485
5312
42
178
591
6152
56
11
577
6319
45
173
585
6128
137
994
449
4972
171
1519
238
2774
Atrial fibrillation and flutter
I48 [45596206]
5.7e-01
6.8e-01
7.9e-01
3.4e+00
1.1e+00
8.1e-01
5.2e-01
cases:18.17%
controls:11.15%
cases:11.53%
controls:6.19%
cases:2.69%
controls:1.23%
cases:2.84%
controls:0.09%
cases:3.65%
controls:1.25%
cases:11.77%
controls:5.58%
cases:18.09%
controls:11.58%
115
706
518
5624
73
392
560
5938
17
78
616
6252
18
6
615
6324
23
79
607
6222
69
333
517
5633
74
497
335
3796
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
6.2e-01
1.3e+00
1.5e+00
—
1.8e+00
9.4e-01
8.9e-01
cases:6.64%
controls:3.67%
cases:6.48%
controls:1.90%
cases:1.90%
controls:0.43%
—
—
cases:2.70%
controls:0.44%
cases:5.97%
controls:2.41%
cases:10.51%
controls:4.59%
42
232
591
6098
41
120
592
6210
12
27
621
6303
—
17
28
613
6273
35
144
551
5822
43
197
366
4096
venlafaxine; oral
N06AX16 [21604745]
1.1e+00
1.0e+00
1.2e+00
—
1.8e+00
1.6e+00
1.4e+00
cases:5.85%
controls:1.94%
cases:3.95%
controls:1.47%
cases:1.58%
controls:0.47%
—
—
cases:3.33%
controls:0.56%
cases:7.00%
controls:1.48%
cases:9.29%
controls:2.42%
37
123
596
6207
25
93
608
6237
10
30
623
6300
—
21
35
609
6266
41
88
545
5878
38
104
371
4189
Physical Medicine And Rehabilitation
25 [38004468]
1.0e+00
9.6e-01
9.2e-01
1.0e+50
2.3e+00
1.6e+00
1.2e+00
cases:16.11%
controls:6.59%
cases:5.53%
controls:2.20%
cases:1.11%
controls:0.44%
cases:3.79%
controls:0.00%
cases:3.02%
controls:0.32%
cases:9.90%
controls:2.21%
cases:16.87%
controls:6.03%
102
417
531
5913
35
139
598
6191
7
28
626
6302
24
0
609
6330
19
20
611
6281
58
132
528
5834
69
259
340
4034
Intravenous
ZX120 [2001311495]
1.3e+00
2.4e+00
—
—
2.3e+00
2.1e+00
1.2e+00
cases:4.11%
controls:1.17%
cases:3.79%
controls:0.36%
—
—
—
—
cases:0.79%
controls:0.08%
cases:3.07%
controls:0.37%
cases:3.67%
controls:1.19%
26
74
607
6256
24
23
609
6307
—
—
5
5
625
6296
18
22
568
5944
15
51
394
4242
CBC panel - Blood by Automated count
58410-2 [40761511]
2.1e-01
4.4e-01
1.2e+00
3.5e+00
1.3e+00
5.8e-01
3.1e-01
cases:52.61%
controls:47.36%
cases:41.23%
controls:31.14%
cases:17.06%
controls:6.10%
cases:10.58%
controls:0.35%
cases:17.46%
controls:5.67%
cases:45.05%
controls:31.41%
cases:62.35%
controls:54.83%
333
2998
300
3332
261
1971
372
4359
108
386
525
5944
67
22
566
6308
110
357
520
5944
264
1874
322
4092
255
2354
154
1939
Platelets [#/volume] in Blood
26515-7 [3007461]
1.4e-01
5.2e-01
1.1e+00
3.5e+00
1.3e+00
5.6e-01
2.5e-01
cases:59.72%
controls:56.19%
cases:60.66%
controls:47.90%
cases:27.01%
controls:10.76%
cases:16.59%
controls:0.62%
cases:29.52%
controls:10.36%
cases:63.31%
controls:49.61%
cases:75.79%
controls:71.00%
378
3557
255
2773
384
3032
249
3298
171
681
462
5649
105
39
528
6291
186
653
444
5648
371
2960
215
3006
310
3048
99
1245
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.4e-01
5.1e-01
1.1e+00
3.5e+00
1.3e+00
5.5e-01
2.4e-01
cases:59.72%
controls:56.29%
cases:60.66%
controls:48.01%
cases:27.01%
controls:10.79%
cases:16.75%
controls:0.62%
cases:29.05%
controls:10.35%
cases:63.14%
controls:49.63%
cases:75.79%
controls:71.12%
378
3563
255
2767
384
3039
249
3291
171
683
462
5647
106
39
527
6291
183
652
447
5649
370
2961
216
3005
310
3053
99
1240
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.4e-01
5.1e-01
1.1e+00
3.5e+00
1.3e+00
5.5e-01
2.4e-01
cases:59.72%
controls:56.26%
cases:60.51%
controls:47.96%
cases:26.86%
controls:10.77%
cases:16.59%
controls:0.62%
cases:29.37%
controls:10.35%
cases:63.14%
controls:49.66%
cases:75.79%
controls:71.07%
378
3561
255
2769
383
3036
250
3294
170
682
463
5648
105
39
528
6291
185
652
445
5649
370
2963
216
3003
310
3051
99
1242
MCH [Entitic mass]
28539-5 [3035941]
1.4e-01
5.1e-01
1.1e+00
3.5e+00
1.3e+00
5.5e-01
2.4e-01
cases:59.72%
controls:56.24%
cases:60.51%
controls:47.90%
cases:26.86%
controls:10.77%
cases:16.59%
controls:0.62%
cases:29.21%
controls:10.35%
cases:63.14%
controls:49.58%
cases:75.79%
controls:71.05%
378
3560
255
2770
383
3032
250
3298
170
682
463
5648
105
39
528
6291
184
652
446
5649
370
2958
216
3008
310
3050
99
1243
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.4e-01
5.1e-01
1.1e+00
3.5e+00
1.3e+00
5.5e-01
2.4e-01
cases:59.72%
controls:56.26%
cases:60.51%
controls:48.01%
cases:26.86%
controls:10.77%
cases:16.59%
controls:0.62%
cases:29.37%
controls:10.35%
cases:63.14%
controls:49.70%
cases:75.79%
controls:71.09%
378
3561
255
2769
383
3039
250
3291
170
682
463
5648
105
39
528
6291
185
652
445
5649
370
2965
216
3001
310
3052
99
1241
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.4e-01
5.1e-01
1.1e+00
3.5e+00
1.3e+00
5.5e-01
2.4e-01
cases:59.72%
controls:56.27%
cases:60.51%
controls:47.98%
cases:26.86%
controls:10.77%
cases:16.59%
controls:0.62%
cases:29.21%
controls:10.38%
cases:63.14%
controls:49.60%
cases:75.79%
controls:71.02%
378
3562
255
2768
383
3037
250
3293
170
682
463
5648
105
39
528
6291
184
654
446
5647
370
2959
216
3007
310
3049
99
1244
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.5e-01
5.1e-01
1.1e+00
3.5e+00
1.3e+00
5.5e-01
2.4e-01
cases:60.03%
controls:56.33%
cases:60.51%
controls:48.01%
cases:26.86%
controls:10.82%
cases:16.75%
controls:0.63%
cases:29.37%
controls:10.36%
cases:63.14%
controls:49.68%
cases:75.79%
controls:71.12%
380
3566
253
2764
383
3039
250
3291
170
685
463
5645
106
40
527
6290
185
653
445
5648
370
2964
216
3002
310
3053
99
1240
Bone marrow biopsy
XW000 [2001310618]
2.4e+00
2.7e+00
—
—
—
—
1.7e+00
cases:4.74%
controls:0.46%
cases:1.90%
controls:0.13%
—
—
—
—
—
—
—
—
cases:2.69%
controls:0.49%
30
29
603
6301
12
8
621
6322
—
—
—
—
11
21
398
4272
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
1.0e+00
1.4e+00
2.0e+00
—
1.8e+00
1.4e+00
1.0e+00
cases:4.11%
controls:1.48%
cases:2.21%
controls:0.54%
cases:1.11%
controls:0.16%
—
—
cases:0.95%
controls:0.16%
cases:3.24%
controls:0.84%
cases:6.11%
controls:2.31%
26
94
607
6236
14
34
619
6296
7
10
626
6320
—
6
10
624
6291
19
50
567
5916
25
99
384
4194
azathioprine; oral, parenteral
L04AX01 [21603927]
1.5e+00
1.9e+00
—
—
—
1.7e+00
1.7e+00
cases:3.79%
controls:0.84%
cases:3.16%
controls:0.51%
—
—
—
—
—
—
cases:2.56%
controls:0.49%
cases:3.18%
controls:0.58%
24
53
609
6277
20
32
613
6298
—
—
—
15
29
571
5937
13
25
396
4268
Emergency Medicine
93 [38004510]
5.9e-01
1.0e+00
2.2e+00
—
1.6e+00
8.0e-01
6.1e-01
cases:33.18%
controls:21.60%
cases:26.54%
controls:11.58%
cases:13.90%
controls:1.83%
—
—
cases:7.94%
controls:1.78%
cases:24.23%
controls:12.54%
cases:45.72%
controls:31.42%
210
1367
423
4963
168
733
465
5597
88
116
545
6214
—
50
112
580
6189
142
748
444
5218
187
1349
222
2944
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
1.8e-01
5.0e-01
1.1e+00
3.5e+00
1.2e+00
4.5e-01
2.0e-01
cases:40.60%
controls:36.26%
cases:41.39%
controls:29.95%
cases:17.85%
controls:6.73%
cases:10.74%
controls:0.38%
cases:19.05%
controls:6.59%
cases:41.64%
controls:31.28%
cases:53.79%
controls:48.85%
257
2295
376
4035
262
1896
371
4434
113
426
520
5904
68
24
565
6306
120
415
510
5886
244
1866
342
4100
220
2097
189
2196
Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
40976-3 [3040853]
1.6e+00
1.7e+00
—
—
—
2.0e+00
1.5e+00
cases:2.37%
controls:0.51%
cases:1.26%
controls:0.24%
—
—
—
—
—
—
cases:1.54%
controls:0.22%
cases:2.20%
controls:0.51%
15
32
618
6298
8
15
625
6315
—
—
—
9
13
577
5953
9
22
400
4271
Emergency Room and Inpatient Visit
ERIP [262]
6.3e-01
1.0e+00
1.9e+00
—
1.6e+00
8.6e-01
6.1e-01
cases:15.80%
controls:9.07%
cases:13.27%
controls:5.18%
cases:4.42%
controls:0.68%
—
—
cases:3.81%
controls:0.78%
cases:12.80%
controls:5.87%
cases:27.38%
controls:17.07%
100
574
533
5756
84
328
549
6002
28
43
605
6287
—
24
49
606
6252
75
350
511
5616
112
733
297
3560
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
1.3e-01
3.8e-01
1.1e+00
3.5e+00
1.2e+00
4.3e-01
3.2e-01
cases:42.65%
controls:39.40%
cases:42.34%
controls:33.41%
cases:18.48%
controls:7.00%
cases:11.22%
controls:0.39%
cases:20.63%
controls:7.17%
cases:45.73%
controls:35.50%
cases:62.35%
controls:54.69%
270
2494
363
3836
268
2115
365
4215
117
443
516
5887
71
25
562
6305
130
452
500
5849
268
2118
318
3848
255
2348
154
1945
prednisolone
S01BA04 [21603621]
7.3e-01
2.8e-01
2.1e+00
—
2.3e+00
1.4e+00
5.3e-01
cases:5.53%
controls:2.73%
cases:1.42%
controls:1.07%
cases:1.42%
controls:0.17%
—
—
cases:0.95%
controls:0.10%
cases:2.90%
controls:0.74%
cases:4.65%
controls:2.80%
35
173
598
6157
9
68
624
6262
9
11
624
6319
—
6
6
624
6295
17
44
569
5922
19
120
390
4173
prednisolone
S03BA02 [21605202]
7.3e-01
2.8e-01
2.1e+00
—
2.3e+00
1.4e+00
5.3e-01
cases:5.53%
controls:2.73%
cases:1.42%
controls:1.07%
cases:1.42%
controls:0.17%
—
—
cases:0.95%
controls:0.10%
cases:2.90%
controls:0.74%
cases:4.65%
controls:2.80%
35
173
598
6157
9
68
624
6262
9
11
624
6319
—
6
6
624
6295
17
44
569
5922
19
120
390
4173
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
6.4e-01
7.7e-01
1.8e+00
—
1.9e+00
7.8e-01
5.5e-01
cases:17.54%
controls:10.13%
cases:12.16%
controls:6.03%
cases:3.95%
controls:0.68%
—
—
cases:3.33%
controls:0.49%
cases:12.80%
controls:6.29%
cases:26.16%
controls:17.03%
111
641
522
5689
77
382
556
5948
25
43
608
6287
—
21
31
609
6270
75
375
511
5591
107
731
302
3562
Blood transfusion
WW500 [2001310603]
1.8e+00
2.6e+00
—
—
—
2.1e+00
—
cases:2.21%
controls:0.38%
cases:2.05%
controls:0.16%
—
—
—
—
—
—
cases:1.71%
controls:0.22%
—
—
14
24
619
6306
13
10
620
6320
—
—
—
10
13
576
5953
—
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.0e-01
5.2e-01
1.1e+00
3.0e+00
1.3e+00
5.4e-01
3.7e-01
cases:56.08%
controls:51.06%
cases:51.82%
controls:38.93%
cases:17.38%
controls:6.68%
cases:4.11%
controls:0.22%
cases:19.52%
controls:6.36%
cases:53.92%
controls:40.48%
cases:72.86%
controls:64.92%
355
3232
278
3098
328
2464
305
3866
110
423
523
5907
26
14
607
6316
123
401
507
5900
316
2415
270
3551
298
2787
111
1506
Monocytes [#/volume] in Blood
26484-6 [3001604]
7.0e-01
1.2e+00
1.3e+00
—
1.6e+00
9.1e-01
7.3e-01
cases:27.80%
controls:16.08%
cases:24.49%
controls:9.24%
cases:6.16%
controls:1.79%
—
—
cases:7.62%
controls:1.65%
cases:21.67%
controls:10.04%
cases:34.47%
controls:20.29%
176
1018
457
5312
155
585
478
5745
39
113
594
6217
—
48
104
582
6197
127
599
459
5367
141
871
268
3422
Case Management Agency
251B00000X [38004193]
2.3e-01
3.7e-01
1.0e+00
3.6e+00
9.2e-01
4.0e-01
1.8e-01
cases:83.57%
controls:80.17%
cases:80.88%
controls:74.52%
cases:57.66%
controls:32.84%
cases:46.76%
controls:2.24%
cases:55.08%
controls:32.84%
cases:82.42%
controls:75.83%
cases:89.98%
controls:88.21%
529
5075
104
1255
512
4717
121
1613
365
2079
268
4251
296
142
337
6188
347
2069
283
4232
483
4524
103
1442
368
3787
41
506
Eosinophils [#/volume] in Blood
26449-9 [3013115]
6.5e-01
1.1e+00
1.3e+00
—
1.6e+00
9.3e-01
7.8e-01
cases:28.12%
controls:16.95%
cases:24.96%
controls:9.73%
cases:6.64%
controls:1.94%
—
—
cases:8.25%
controls:1.79%
cases:22.53%
controls:10.33%
cases:36.92%
controls:21.10%
178
1073
455
5257
158
616
475
5714
42
123
591
6207
—
52
113
578
6188
132
616
454
5350
151
906
258
3387
Basophils [#/volume] in Blood
26444-0 [3006315]
6.9e-01
1.2e+00
1.3e+00
—
1.6e+00
9.0e-01
7.2e-01
cases:27.80%
controls:16.15%
cases:24.49%
controls:9.27%
cases:6.16%
controls:1.80%
—
—
cases:7.78%
controls:1.67%
cases:21.67%
controls:10.07%
cases:34.47%
controls:20.38%
176
1022
457
5308
155
587
478
5743
39
114
594
6216
—
49
105
581
6196
127
601
459
5365
141
875
268
3418
hydroxychloroquine; oral
P01BA02 [21604889]
9.6e-01
1.1e+00
6.6e-01
—
1.7e+00
1.2e+00
1.4e+00
cases:4.42%
controls:1.74%
cases:3.95%
controls:1.34%
cases:0.79%
controls:0.41%
—
—
cases:1.59%
controls:0.30%
cases:4.10%
controls:1.27%
cases:4.89%
controls:1.26%
28
110
605
6220
25
85
608
6245
5
26
628
6304
—
10
19
620
6282
24
76
562
5890
20
54
389
4239
Psychiatry
26 [38004469]
6.0e-01
1.0e+00
1.4e+00
—
1.2e+00
9.8e-01
1.1e+00
cases:7.58%
controls:4.33%
cases:4.74%
controls:1.72%
cases:2.53%
controls:0.63%
—
—
cases:2.22%
controls:0.65%
cases:4.61%
controls:1.78%
cases:8.56%
controls:3.14%
48
274
585
6056
30
109
603
6221
16
40
617
6290
—
14
41
616
6260
27
106
559
5860
35
135
374
4158
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
7.1e-01
1.1e+00
1.2e+00
—
1.6e+00
9.0e-01
7.0e-01
cases:28.75%
controls:16.56%
cases:24.96%
controls:9.61%
cases:6.16%
controls:1.88%
—
—
cases:8.25%
controls:1.73%
cases:22.01%
controls:10.27%
cases:34.47%
controls:20.75%
182
1048
451
5282
158
608
475
5722
39
119
594
6211
—
52
109
578
6192
129
613
457
5353
141
891
268
3402
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
4.9e-01
9.5e-01
1.9e+00
—
1.7e+00
8.7e-01
4.1e-01
cases:20.06%
controls:13.27%
cases:14.69%
controls:6.27%
cases:5.69%
controls:0.92%
—
—
cases:3.33%
controls:0.63%
cases:12.97%
controls:5.88%
cases:24.94%
controls:18.05%
127
840
506
5490
93
397
540
5933
36
58
597
6272
—
21
40
609
6261
76
351
510
5615
102
775
307
3518
clindamycin; oral, parenteral
J01FF01 [21602985]
1.7e-01
1.2e+00
2.6e+00
—
—
1.3e+00
1.1e+00
cases:4.42%
controls:3.74%
cases:3.00%
controls:0.90%
cases:1.11%
controls:0.08%
—
—
—
—
cases:2.56%
controls:0.74%
cases:8.80%
controls:3.00%
28
237
605
6093
19
57
614
6273
7
5
626
6325
—
—
15
44
571
5922
36
129
373
4164
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
6.8e-01
1.1e+00
1.3e+00
2.1e+00
1.6e+00
8.6e-01
7.2e-01
cases:27.01%
controls:15.85%
cases:23.38%
controls:9.04%
cases:6.16%
controls:1.72%
cases:0.79%
controls:0.09%
cases:7.94%
controls:1.75%
cases:20.31%
controls:9.77%
cases:32.27%
controls:18.87%
171
1003
462
5327
148
572
485
5758
39
109
594
6221
5
6
628
6324
50
110
580
6191
119
583
467
5383
132
810
277
3483
Differential panel, method unspecified - Blood
69738-3 [42870588]
7.4e-01
9.7e-01
1.4e+00
—
1.5e+00
8.7e-01
8.4e-01
cases:20.70%
controls:11.06%
cases:15.01%
controls:6.30%
cases:4.74%
controls:1.25%
—
—
cases:5.56%
controls:1.32%
cases:14.33%
controls:6.57%
cases:25.18%
controls:12.67%
131
700
502
5630
95
399
538
5931
30
79
603
6251
—
35
83
595
6218
84
392
502
5574
103
544
306
3749
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
7.6e-01
8.8e-01
1.6e+00
—
1.5e+00
8.9e-01
6.7e-01
cases:17.06%
controls:8.80%
cases:8.53%
controls:3.71%
cases:2.05%
controls:0.43%
—
—
cases:1.90%
controls:0.44%
cases:9.04%
controls:3.91%
cases:19.56%
controls:11.02%
108
557
525
5773
54
235
579
6095
13
27
620
6303
—
12
28
618
6273
53
233
533
5733
80
473
329
3820
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
6.7e-01
1.1e+00
1.3e+00
—
1.6e+00
8.5e-01
6.9e-01
cases:26.54%
controls:15.56%
cases:22.91%
controls:8.77%
cases:6.00%
controls:1.71%
—
—
cases:7.46%
controls:1.65%
cases:19.62%
controls:9.49%
cases:31.54%
controls:18.70%
168
985
465
5345
145
555
488
5775
38
108
595
6222
—
47
104
583
6197
115
566
471
5400
129
803
280
3490
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
6.5e-01
1.1e+00
—
—
2.4e+00
1.2e+00
8.6e-01
cases:5.37%
controls:2.89%
cases:3.63%
controls:1.23%
—
—
—
—
cases:1.27%
controls:0.11%
cases:3.58%
controls:1.16%
cases:8.80%
controls:3.94%
34
183
599
6147
23
78
610
6252
—
—
8
7
622
6294
21
69
565
5897
36
169
373
4124
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
6.5e-01
1.1e+00
—
—
2.4e+00
1.2e+00
8.6e-01
cases:5.37%
controls:2.89%
cases:3.63%
controls:1.23%
—
—
—
—
cases:1.27%
controls:0.11%
cases:3.58%
controls:1.16%
cases:8.80%
controls:3.94%
34
183
599
6147
23
78
610
6252
—
—
8
7
622
6294
21
69
565
5897
36
169
373
4124
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
6.5e-01
1.1e+00
1.3e+00
2.3e+00
1.5e+00
8.3e-01
7.6e-01
cases:26.22%
controls:15.66%
cases:22.59%
controls:8.78%
cases:6.00%
controls:1.67%
cases:0.79%
controls:0.08%
cases:7.30%
controls:1.67%
cases:19.45%
controls:9.50%
cases:32.52%
controls:18.45%
166
991
467
5339
143
556
490
5774
38
106
595
6224
5
5
628
6325
46
105
584
6196
114
567
472
5399
133
792
276
3501
Monocytes/Leukocytes in Blood
26485-3 [3019069]
6.4e-01
1.1e+00
1.3e+00
2.3e+00
1.5e+00
8.2e-01
7.5e-01
cases:26.22%
controls:15.72%
cases:22.75%
controls:8.77%
cases:6.00%
controls:1.66%
cases:0.79%
controls:0.08%
cases:7.30%
controls:1.67%
cases:19.28%
controls:9.50%
cases:32.52%
controls:18.54%
166
995
467
5335
144
555
489
5775
38
105
595
6225
5
5
628
6325
46
105
584
6196
113
567
473
5399
133
796
276
3497
ciclosporin; oral, parenteral
L04AD01 [21603924]
2.2e+00
2.1e+00
—
—
—
2.0e+00
—
cases:2.05%
controls:0.24%
cases:1.58%
controls:0.21%
—
—
—
—
—
—
cases:1.54%
controls:0.22%
—
—
13
15
620
6315
10
13
623
6317
—
—
—
9
13
577
5953
—
Chronic kidney disease, unspecified
N18.9 [45553438]
8.9e-01
1.3e+00
2.4e+00
1.0e+50
1.4e+00
1.3e+00
1.1e+00
cases:2.84%
controls:1.18%
cases:2.84%
controls:0.76%
cases:1.26%
controls:0.11%
cases:1.11%
controls:0.00%
cases:0.95%
controls:0.24%
cases:3.75%
controls:1.07%
cases:6.36%
controls:2.19%
18
75
615
6255
18
48
615
6282
8
7
625
6323
7
0
626
6330
6
15
624
6286
22
64
564
5902
26
94
383
4199
Basophils/Leukocytes in Blood
30180-4 [3022096]
6.5e-01
1.1e+00
1.3e+00
—
1.6e+00
8.3e-01
7.2e-01
cases:26.07%
controls:15.59%
cases:22.43%
controls:8.78%
cases:5.85%
controls:1.66%
—
—
cases:7.30%
controls:1.63%
cases:19.45%
controls:9.52%
cases:31.78%
controls:18.54%
165
987
468
5343
142
556
491
5774
37
105
596
6225
—
46
103
584
6198
114
568
472
5398
130
796
279
3497
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
4.9e-01
8.4e-01
1.7e+00
—
1.7e+00
7.6e-01
5.9e-01
cases:29.23%
controls:20.11%
cases:19.75%
controls:9.64%
cases:6.95%
controls:1.30%
—
—
cases:6.19%
controls:1.22%
cases:17.58%
controls:9.03%
cases:38.39%
controls:25.60%
185
1273
448
5057
125
610
508
5720
44
82
589
6248
—
39
77
591
6224
103
539
483
5427
157
1099
252
3194
FEV1/FVC
19926-5 [3011505]
9.3e-01
1.6e+00
—
—
—
2.0e+00
1.6e+00
cases:7.42%
controls:3.06%
cases:3.63%
controls:0.74%
—
—
—
—
—
—
cases:3.92%
controls:0.57%
cases:8.07%
controls:1.77%
47
194
586
6136
23
47
610
6283
—
—
—
23
34
563
5932
33
76
376
4217
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
9.3e-01
1.6e+00
—
—
—
2.0e+00
1.6e+00
cases:7.42%
controls:3.06%
cases:3.63%
controls:0.74%
—
—
—
—
—
—
cases:3.92%
controls:0.57%
cases:8.07%
controls:1.77%
47
194
586
6136
23
47
610
6283
—
—
—
23
34
563
5932
33
76
376
4217
FEV1
20150-9 [3024653]
9.3e-01
1.6e+00
—
—
—
2.0e+00
1.6e+00
cases:7.42%
controls:3.06%
cases:3.63%
controls:0.74%
—
—
—
—
—
—
cases:3.92%
controls:0.57%
cases:8.07%
controls:1.77%
47
194
586
6136
23
47
610
6283
—
—
—
23
34
563
5932
33
76
376
4217
Laboratory Visit
OMOP4822461 [32036]
1.1e-01
3.9e-01
1.0e+00
3.1e+00
1.0e+00
5.0e-01
1.8e-01
cases:62.56%
controls:60.02%
cases:65.40%
controls:56.22%
cases:38.55%
controls:18.21%
cases:19.27%
controls:1.09%
cases:38.89%
controls:18.38%
cases:69.11%
controls:57.64%
cases:77.75%
controls:74.49%
396
3799
237
2531
414
3559
219
2771
244
1153
389
5177
122
69
511
6261
245
1158
385
5143
405
3439
181
2527
318
3198
91
1095
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
5.6e-01
9.5e-01
1.3e+00
—
1.7e+00
8.1e-01
6.8e-01
cases:39.97%
controls:27.61%
cases:28.91%
controls:13.60%
cases:6.64%
controls:1.94%
—
—
cases:8.57%
controls:1.62%
cases:26.79%
controls:13.98%
cases:48.41%
controls:32.31%
253
1748
380
4582
183
861
450
5469
42
123
591
6207
—
54
102
576
6199
157
834
429
5132
198
1387
211
2906
FEV1/FVC --post bronchodilation
69970-2 [42868459]
1.0e+00
1.5e+00
—
—
—
1.9e+00
1.5e+00
cases:6.79%
controls:2.62%
cases:2.84%
controls:0.63%
—
—
—
—
—
—
cases:3.07%
controls:0.45%
cases:6.60%
controls:1.58%
43
166
590
6164
18
40
615
6290
—
—
—
18
27
568
5939
27
68
382
4225
FEV1 percent change
69983-5 [42868472]
1.0e+00
1.5e+00
—
—
—
1.9e+00
1.5e+00
cases:6.79%
controls:2.62%
cases:2.84%
controls:0.63%
—
—
—
—
—
—
cases:3.07%
controls:0.45%
cases:6.60%
controls:1.58%
43
166
590
6164
18
40
615
6290
—
—
—
18
27
568
5939
27
68
382
4225
FEV1 --post bronchodilation
20155-8 [3023550]
1.0e+00
1.5e+00
—
—
—
1.9e+00
1.5e+00
cases:6.79%
controls:2.62%
cases:2.84%
controls:0.63%
—
—
—
—
—
—
cases:3.07%
controls:0.45%
cases:6.60%
controls:1.58%
43
166
590
6164
18
40
615
6290
—
—
—
18
27
568
5939
27
68
382
4225
FVC percent change Respiratory system
69982-7 [42868471]
1.0e+00
1.5e+00
—
—
—
1.9e+00
1.5e+00
cases:6.79%
controls:2.62%
cases:2.84%
controls:0.63%
—
—
—
—
—
—
cases:3.07%
controls:0.45%
cases:6.60%
controls:1.58%
43
166
590
6164
18
40
615
6290
—
—
—
18
27
568
5939
27
68
382
4225
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
1.0e+00
1.5e+00
—
—
—
1.9e+00
1.5e+00
cases:6.79%
controls:2.62%
cases:2.84%
controls:0.63%
—
—
—
—
—
—
cases:3.07%
controls:0.45%
cases:6.60%
controls:1.58%
43
166
590
6164
18
40
615
6290
—
—
—
18
27
568
5939
27
68
382
4225
lamotrigine; oral
N03AX09 [21604431]
1.1e+00
2.0e+00
—
—
—
2.1e+00
1.8e+00
cases:1.42%
controls:0.47%
cases:1.90%
controls:0.25%
—
—
—
—
—
—
cases:2.39%
controls:0.30%
cases:3.18%
controls:0.54%
9
30
624
6300
12
16
621
6314
—
—
—
14
18
572
5948
13
23
396
4270
Short blood count panel - Blood
55429-5 [40758558]
5.8e-01
8.9e-01
1.3e+00
—
1.8e+00
7.7e-01
5.6e-01
cases:13.74%
controls:8.21%
cases:10.27%
controls:4.47%
cases:3.00%
controls:0.81%
—
—
cases:4.29%
controls:0.75%
cases:9.04%
controls:4.39%
cases:17.11%
controls:10.58%
87
520
546
5810
65
283
568
6047
19
51
614
6279
—
27
47
603
6254
53
262
533
5704
70
454
339
3839
Pulmonary Disease
29 [38004472]
8.1e-01
1.0e+00
1.3e+00
—
1.1e+00
8.9e-01
8.0e-01
cases:21.96%
controls:11.11%
cases:14.38%
controls:5.80%
cases:3.32%
controls:0.96%
—
—
cases:4.13%
controls:1.35%
cases:12.46%
controls:5.51%
cases:21.27%
controls:10.83%
139
703
494
5627
91
367
542
5963
21
61
612
6269
—
26
85
604
6216
73
329
513
5637
87
465
322
3828
Bacteria [Presence] in Urine
87829-8 [36304419]
6.4e-01
7.2e-01
1.6e+00
1.0e+50
1.7e+00
6.7e-01
5.0e-01
cases:14.22%
controls:8.07%
cases:9.32%
controls:4.76%
cases:2.69%
controls:0.54%
cases:1.26%
controls:0.00%
cases:3.65%
controls:0.67%
cases:9.39%
controls:5.01%
cases:19.07%
controls:12.56%
90
511
543
5819
59
301
574
6029
17
34
616
6296
8
0
625
6330
23
42
607
6259
55
299
531
5667
78
539
331
3754
pH of Serum or Plasma
2753-2 [3018418]
5.2e-01
8.7e-01
1.1e+00
—
1.8e+00
8.7e-01
6.9e-01
cases:16.11%
controls:10.25%
cases:12.16%
controls:5.47%
cases:3.00%
controls:1.01%
—
—
cases:4.76%
controls:0.81%
cases:12.12%
controls:5.45%
cases:22.98%
controls:13.07%
102
649
531
5681
77
346
556
5984
19
64
614
6266
—
30
51
600
6250
71
325
515
5641
94
561
315
3732
Other and unspecified abdominal pain
R10.4 [45568113]
8.0e-01
9.5e-01
2.2e+00
—
1.5e+00
9.7e-01
9.1e-01
cases:12.80%
controls:6.18%
cases:4.90%
controls:1.94%
cases:1.58%
controls:0.17%
—
—
cases:0.79%
controls:0.17%
cases:4.95%
controls:1.93%
cases:13.94%
controls:6.10%
81
391
552
5939
31
123
602
6207
10
11
623
6319
—
5
11
625
6290
29
115
557
5851
57
262
352
4031
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
9.2e-01
1.4e+00
2.6e+00
—
—
9.3e-01
4.7e-01
cases:8.37%
controls:3.51%
cases:4.90%
controls:1.31%
cases:1.74%
controls:0.13%
—
—
—
—
cases:3.41%
controls:1.37%
cases:5.62%
controls:3.59%
53
222
580
6108
31
83
602
6247
11
8
622
6322
—
—
20
82
566
5884
23
154
386
4139
CD3 cells [#/volume] in Blood
8122-4 [3011412]
2.5e+00
—
—
—
—
—
3.3e+00
cases:2.37%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
cases:2.93%
controls:0.12%
15
12
618
6318
—
—
—
—
—
12
5
397
4288
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
4.9e-01
7.5e-01
1.3e+00
—
1.6e+00
9.8e-01
6.9e-01
cases:24.01%
controls:16.24%
cases:15.80%
controls:8.10%
cases:4.90%
controls:1.37%
—
—
cases:6.03%
controls:1.32%
cases:18.94%
controls:8.03%
cases:33.50%
controls:20.24%
152
1028
481
5302
100
513
533
5817
31
87
602
6243
—
38
83
592
6218
111
479
475
5487
137
869
272
3424
cefalexin; oral
J01DB01 [21602870]
7.4e-01
8.7e-01
1.8e+00
—
1.0e+00
6.1e-01
7.2e-01
cases:45.34%
controls:28.37%
cases:18.17%
controls:8.50%
cases:5.37%
controls:0.92%
—
—
cases:2.54%
controls:0.94%
cases:15.02%
controls:8.77%
cases:41.56%
controls:25.69%
287
1796
346
4534
115
538
518
5792
34
58
599
6272
—
16
59
614
6242
88
523
498
5443
170
1103
239
3190
Sicca syndrome [Sjögren]
M35.0 [45562711]
1.8e+00
2.0e+00
—
—
—
2.0e+00
1.9e+00
cases:1.90%
controls:0.33%
cases:1.26%
controls:0.17%
—
—
—
—
—
—
cases:1.37%
controls:0.18%
cases:1.22%
controls:0.19%
12
21
621
6309
8
11
625
6319
—
—
—
8
11
578
5955
5
8
404
4285
methylprednisolone; oral, parenteral
H02AB04 [21602732]
1.3e+00
1.7e+00
1.7e+00
—
—
1.6e+00
1.1e+00
cases:5.21%
controls:1.50%
cases:3.63%
controls:0.66%
cases:0.79%
controls:0.14%
—
—
—
—
cases:2.90%
controls:0.59%
cases:3.91%
controls:1.30%
33
95
600
6235
23
42
610
6288
5
9
628
6321
—
—
17
35
569
5931
16
56
393
4237
Dyspnoea
R06.0 [45558449]
9.5e-01
9.0e-01
1.6e+00
—
1.7e+00
7.3e-01
6.1e-01
cases:13.74%
controls:5.80%
cases:4.90%
controls:2.05%
cases:1.58%
controls:0.32%
—
—
cases:1.43%
controls:0.27%
cases:4.44%
controls:2.18%
cases:11.74%
controls:6.73%
87
367
546
5963
31
130
602
6200
10
20
623
6310
—
9
17
621
6284
26
130
560
5836
48
289
361
4004
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
5.9e-02
3.6e-01
9.6e-01
3.3e+00
1.1e+00
2.8e-01
3.5e-02
cases:41.86%
controls:40.43%
cases:40.76%
controls:32.35%
cases:16.75%
controls:7.12%
cases:11.53%
controls:0.47%
cases:18.41%
controls:6.95%
cases:39.25%
controls:32.84%
cases:51.59%
controls:50.71%
265
2559
368
3771
258
2048
375
4282
106
451
527
5879
73
30
560
6300
116
438
514
5863
230
1959
356
4007
211
2177
198
2116
Proteinase 3 Ab [Units/volume] in Serum
6968-2 [3009445]
1.3e+00
1.5e+00
—
—
—
1.9e+00
1.1e+00
cases:3.48%
controls:1.00%
cases:1.74%
controls:0.41%
—
—
—
—
—
—
cases:2.22%
controls:0.34%
cases:3.42%
controls:1.19%
22
63
611
6267
11
26
622
6304
—
—
—
13
20
573
5946
14
51
395
4242
Asthma, unspecified
J45.9 [45562456]
1.1e+00
1.1e+00
1.8e+00
—
1.0e+00
1.1e+00
7.1e-01
cases:12.01%
controls:4.47%
cases:6.79%
controls:2.48%
cases:2.21%
controls:0.38%
—
—
cases:1.11%
controls:0.41%
cases:5.97%
controls:2.08%
cases:10.27%
controls:5.33%
76
283
557
6047
43
157
590
6173
14
24
619
6306
—
7
26
623
6275
35
124
551
5842
42
229
367
4064
Dermatitis, unspecified
L30.9 [45572271]
8.2e-01
1.3e+00
2.6e+00
—
2.3e+00
9.5e-01
5.5e-01
cases:6.16%
controls:2.81%
cases:3.32%
controls:0.95%
cases:1.11%
controls:0.08%
—
—
cases:0.79%
controls:0.08%
cases:3.24%
controls:1.27%
cases:6.60%
controls:3.94%
39
178
594
6152
21
60
612
6270
7
5
626
6325
—
5
5
625
6296
19
76
567
5890
27
169
382
4124
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
117 [2001600117]
1.9e+00
2.0e+00
—
—
—
1.4e+00
1.8e+00
cases:3.48%
controls:0.52%
cases:1.11%
controls:0.16%
—
—
—
—
—
—
cases:0.85%
controls:0.22%
cases:1.96%
controls:0.33%
22
33
611
6297
7
10
626
6320
—
—
—
5
13
581
5953
8
14
401
4279
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
1.7e+00
2.3e+00
—
—
—
1.6e+00
1.7e+00
cases:3.00%
controls:0.57%
cases:1.90%
controls:0.19%
—
—
—
—
—
—
cases:1.19%
controls:0.23%
cases:1.96%
controls:0.37%
19
36
614
6294
12
12
621
6318
—
—
—
7
14
579
5952
8
16
401
4277
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
9.8e-01
1.1e+00
2.3e+00
—
1.0e+00
1.3e+00
5.4e-01
cases:6.00%
controls:2.34%
cases:4.27%
controls:1.42%
cases:1.42%
controls:0.14%
—
—
cases:0.79%
controls:0.29%
cases:5.46%
controls:1.63%
cases:9.54%
controls:5.78%
38
148
595
6182
27
90
606
6240
9
9
624
6321
—
5
18
625
6283
32
97
554
5869
39
248
370
4045
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
8.1e-01
7.7e-01
1.9e+00
1.0e+50
1.5e+00
7.1e-01
4.2e-01
cases:13.11%
controls:6.30%
cases:6.95%
controls:3.35%
cases:2.37%
controls:0.38%
cases:0.95%
controls:0.00%
cases:2.06%
controls:0.46%
cases:6.48%
controls:3.29%
cases:12.71%
controls:8.71%
83
399
550
5931
44
212
589
6118
15
24
618
6306
6
0
627
6330
13
29
617
6272
38
196
548
5770
52
374
357
3919
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
4.7e-01
7.4e-01
1.2e+00
—
1.6e+00
9.5e-01
6.4e-01
cases:25.91%
controls:17.87%
cases:18.48%
controls:9.73%
cases:5.06%
controls:1.60%
—
—
cases:7.30%
controls:1.51%
cases:21.67%
controls:9.64%
cases:36.92%
controls:23.64%
164
1131
469
5199
117
616
516
5714
32
101
601
6229
—
46
95
584
6206
127
575
459
5391
151
1015
258
3278
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
9.9e-01
1.6e+00
2.2e+00
—
—
5.1e-01
9.2e-01
cases:7.11%
controls:2.76%
cases:4.27%
controls:0.93%
cases:0.95%
controls:0.11%
—
—
—
—
cases:1.88%
controls:1.14%
cases:7.33%
controls:3.05%
45
175
588
6155
27
59
606
6271
6
7
627
6323
—
—
11
68
575
5898
30
131
379
4162
Outpatient Hospital
22 [8756]
5.2e-01
8.1e-01
1.3e+00
—
1.4e+00
8.6e-01
7.3e-01
cases:38.55%
controls:27.11%
cases:15.01%
controls:7.30%
cases:3.48%
controls:0.93%
—
—
cases:3.65%
controls:0.97%
cases:13.99%
controls:6.47%
cases:28.36%
controls:16.03%
244
1716
389
4614
95
462
538
5868
22
59
611
6271
—
23
61
607
6240
82
386
504
5580
116
688
293
3605
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
6.6e-01
6.9e-01
1.3e+00
—
1.3e+00
8.0e-01
8.4e-01
cases:16.90%
controls:9.53%
cases:8.06%
controls:4.22%
cases:3.00%
controls:0.82%
—
—
cases:2.54%
controls:0.70%
cases:8.36%
controls:3.94%
cases:18.09%
controls:8.74%
107
603
526
5727
51
267
582
6063
19
52
614
6278
—
16
44
614
6257
49
235
537
5731
74
375
335
3918
Medical doctor
Z2221 [2001311556]
5.9e-01
9.0e-01
1.6e+00
—
2.0e+00
1.3e+00
8.6e-01
cases:9.79%
controls:5.67%
cases:3.48%
controls:1.44%
cases:0.79%
controls:0.16%
—
—
cases:1.11%
controls:0.16%
cases:3.92%
controls:1.11%
cases:7.33%
controls:3.24%
62
359
571
5971
22
91
611
6239
5
10
628
6320
—
7
10
623
6291
23
66
563
5900
30
139
379
4154
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
1.0e+00
1.1e+00
2.2e+00
—
1.4e+00
1.2e+00
4.8e-01
cases:6.00%
controls:2.24%
cases:4.11%
controls:1.44%
cases:1.42%
controls:0.16%
—
—
cases:1.11%
controls:0.29%
cases:5.80%
controls:1.74%
cases:9.78%
controls:6.31%
38
142
595
6188
26
91
607
6239
9
10
624
6320
—
7
18
623
6283
34
104
552
5862
40
271
369
4022
Base excess in Arterial blood by calculation
1925-7 [3003396]
6.4e-01
1.1e+00
—
—
2.4e+00
1.2e+00
8.3e-01
cases:5.37%
controls:2.91%
cases:3.48%
controls:1.23%
—
—
—
—
cases:1.27%
controls:0.11%
cases:3.75%
controls:1.14%
cases:8.56%
controls:3.94%
34
184
599
6146
22
78
611
6252
—
—
8
7
622
6294
22
68
564
5898
35
169
374
4124
High resolution CT examination of lungs
GD1DD [2001303632]
1.1e+00
1.8e+00
—
—
—
2.7e+00
1.3e+00
cases:2.53%
controls:0.84%
cases:1.26%
controls:0.22%
—
—
—
—
—
—
cases:1.88%
controls:0.13%
cases:2.44%
controls:0.70%
16
53
617
6277
8
14
625
6316
—
—
—
11
8
575
5958
10
30
399
4263
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
6.0e-01
7.3e-01
1.4e+00
—
1.7e+00
6.9e-01
4.7e-01
cases:19.91%
controls:11.96%
cases:12.64%
controls:6.51%
cases:3.32%
controls:0.87%
—
—
cases:4.76%
controls:0.94%
cases:11.95%
controls:6.37%
cases:23.72%
controls:16.26%
126
757
507
5573
80
412
553
5918
21
55
612
6275
—
30
59
600
6242
70
380
516
5586
97
698
312
3595
CD3-CD16+CD56+ (Natural killer) cells [#/volume] in Blood
9728-7 [3025271]
2.4e+00
—
—
—
—
—
3.1e+00
cases:1.58%
controls:0.14%
—
—
—
—
—
—
—
—
—
—
cases:2.44%
controls:0.12%
10
9
623
6321
—
—
—
—
—
10
5
399
4288
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
5.9e-01
8.7e-01
1.3e+00
—
1.2e+00
8.1e-01
6.3e-01
cases:23.70%
controls:14.64%
cases:17.38%
controls:8.07%
cases:4.58%
controls:1.31%
—
—
cases:4.29%
controls:1.29%
cases:17.06%
controls:8.36%
cases:32.27%
controls:20.24%
150
927
483
5403
110
511
523
5819
29
83
604
6247
—
27
81
603
6220
100
499
486
5467
132
869
277
3424
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
8.4e-01
1.0e+00
1.8e+00
—
1.4e+00
9.8e-01
8.1e-01
cases:5.21%
controls:2.32%
cases:4.11%
controls:1.53%
cases:1.58%
controls:0.27%
—
—
cases:1.27%
controls:0.32%
cases:4.44%
controls:1.71%
cases:6.85%
controls:3.17%
33
147
600
6183
26
97
607
6233
10
17
623
6313
—
8
20
622
6281
26
102
560
5864
28
136
381
4157
Supplier / Service Provider
OMOP5117446 [33004]
-1.1e-01
2.4e-01
6.0e-01
—
2.1e+00
2.7e+00
2.7e+00
cases:23.22%
controls:25.18%
cases:8.69%
controls:6.97%
cases:1.26%
controls:0.70%
—
—
cases:0.79%
controls:0.10%
cases:8.19%
controls:0.57%
cases:20.78%
controls:1.77%
147
1594
486
4736
55
441
578
5889
8
44
625
6286
—
5
6
625
6295
48
34
538
5932
85
76
324
4217
Myeloperoxidase Ab [Units/volume] in Serum
6969-0 [3023150]
1.8e+00
1.9e+00
—
—
—
1.6e+00
1.7e+00
cases:1.58%
controls:0.27%
cases:1.26%
controls:0.19%
—
—
—
—
—
—
cases:0.85%
controls:0.17%
cases:2.93%
controls:0.54%
10
17
623
6313
8
12
625
6318
—
—
—
5
10
581
5956
12
23
397
4270
Oxygen saturation in Arterial blood
2708-6 [3016502]
6.4e-01
1.2e+00
—
—
2.4e+00
1.0e+00
7.3e-01
cases:4.58%
controls:2.46%
cases:3.16%
controls:1.00%
—
—
—
—
cases:1.27%
controls:0.11%
cases:2.90%
controls:1.04%
cases:7.33%
controls:3.66%
29
156
604
6174
20
63
613
6267
—
—
8
7
622
6294
17
62
569
5904
30
157
379
4136
CD3+CD4+ (T4 helper) cells [#/volume] in Blood
24467-3 [3028167]
2.6e+00
—
—
—
—
—
2.8e+00
cases:1.42%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.12%
9
7
624
6323
—
—
—
—
—
8
5
401
4288
hydroxyzine; oral, parenteral
N05BB01 [21604590]
7.0e-01
1.4e+00
2.0e+00
—
—
1.3e+00
8.8e-01
cases:4.58%
controls:2.32%
cases:3.95%
controls:1.00%
cases:1.26%
controls:0.17%
—
—
—
—
cases:3.24%
controls:0.94%
cases:4.16%
controls:1.77%
29
147
604
6183
25
63
608
6267
8
11
625
6319
—
—
19
56
567
5910
17
76
392
4217
pH of Arterial blood
2744-1 [3019977]
6.0e-01
1.1e+00
—
—
2.3e+00
1.2e+00
7.8e-01
cases:5.21%
controls:2.94%
cases:3.63%
controls:1.22%
—
—
—
—
cases:1.11%
controls:0.11%
cases:3.41%
controls:1.11%
cases:8.31%
controls:4.01%
33
186
600
6144
23
77
610
6253
—
—
7
7
623
6294
20
66
566
5900
34
172
375
4121
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
6.7e-01
7.2e-01
1.6e+00
—
1.6e+00
7.2e-01
3.5e-01
cases:17.22%
controls:9.59%
cases:11.53%
controls:5.97%
cases:3.16%
controls:0.66%
—
—
cases:4.29%
controls:0.87%
cases:11.95%
controls:6.20%
cases:21.27%
controls:16.03%
109
607
524
5723
73
378
560
5952
20
42
613
6288
—
27
55
603
6246
70
370
516
5596
87
688
322
3605
mycophenolic acid; oral, parenteral
L04AA06 [21603896]
1.8e+00
1.9e+00
1.8e+00
—
—
1.6e+00
1.5e+00
cases:1.90%
controls:0.32%
cases:2.21%
controls:0.33%
cases:0.79%
controls:0.13%
—
—
—
—
cases:1.54%
controls:0.32%
cases:1.71%
controls:0.37%
12
20
621
6310
14
21
619
6309
5
8
628
6322
—
—
9
19
577
5947
7
16
402
4277
Normoblasts [#/volume] in Blood
715-3 [3021589]
5.0e-01
7.9e-01
1.4e+00
—
1.4e+00
6.7e-01
5.3e-01
cases:21.48%
controls:14.27%
cases:21.33%
controls:10.95%
cases:9.00%
controls:2.46%
—
—
cases:9.05%
controls:2.43%
cases:20.82%
controls:11.87%
cases:31.05%
controls:20.92%
136
903
497
5427
135
693
498
5637
57
156
576
6174
—
57
153
573
6148
122
708
464
5258
127
898
282
3395
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
8.1e-01
1.0e+00
—
—
2.3e+00
1.1e+00
4.6e-01
cases:4.27%
controls:1.94%
cases:2.84%
controls:1.03%
—
—
—
—
cases:1.11%
controls:0.11%
cases:2.56%
controls:0.89%
cases:5.87%
controls:3.77%
27
123
606
6207
18
65
615
6265
—
—
7
7
623
6294
15
53
571
5913
24
162
385
4131
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
6.2e-01
8.3e-01
1.4e+00
1.0e+50
1.6e+00
5.2e-01
7.1e-01
cases:15.96%
controls:9.23%
cases:7.27%
controls:3.30%
cases:1.90%
controls:0.46%
cases:1.74%
controls:0.00%
cases:2.06%
controls:0.44%
cases:6.83%
controls:4.16%
cases:20.78%
controls:11.41%
101
584
532
5746
46
209
587
6121
12
29
621
6301
11
0
622
6330
13
28
617
6273
40
248
546
5718
85
490
324
3803
Headache
R51.80 [2000503603]
1.1e+00
1.2e+00
—
1.0e+50
—
1.7e+00
1.2e+00
cases:6.16%
controls:2.10%
cases:2.84%
controls:0.92%
—
—
cases:0.79%
controls:0.00%
—
—
cases:3.07%
controls:0.59%
cases:6.11%
controls:1.96%
39
133
594
6197
18
58
615
6272
—
5
0
628
6330
—
18
35
568
5931
25
84
384
4209
Lymphocyte T-cell and B-cell and Natural killer subsets panel - Blood
80721-4 [21493690]
2.4e+00
—
—
—
—
—
2.7e+00
cases:1.58%
controls:0.14%
—
—
—
—
—
—
—
—
—
—
cases:1.71%
controls:0.12%
10
9
623
6321
—
—
—
—
—
7
5
402
4288
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
8.2e-01
9.3e-01
—
—
1.9e+00
8.0e-01
6.3e-01
cases:7.90%
controls:3.65%
cases:6.00%
controls:2.46%
—
—
—
—
cases:1.75%
controls:0.25%
cases:5.97%
controls:2.77%
cases:12.71%
controls:7.22%
50
231
583
6099
38
156
595
6174
—
—
11
16
619
6285
35
165
551
5801
52
310
357
3983
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
6.1e-01
6.0e-01
1.7e+00
—
1.6e+00
6.5e-01
4.1e-01
cases:14.38%
controls:8.39%
cases:9.00%
controls:5.15%
cases:2.84%
controls:0.55%
—
—
cases:3.65%
controls:0.76%
cases:9.90%
controls:5.45%
cases:18.83%
controls:13.39%
91
531
542
5799
57
326
576
6004
18
35
615
6295
—
23
48
607
6253
58
325
528
5641
77
575
332
3718
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
7.0e-01
1.1e+00
1.6e+00
—
1.7e+00
7.5e-01
6.1e-01
cases:5.06%
controls:2.58%
cases:4.58%
controls:1.61%
cases:1.90%
controls:0.39%
—
—
cases:2.06%
controls:0.37%
cases:3.92%
controls:1.89%
cases:6.11%
controls:3.40%
32
163
601
6167
29
102
604
6228
12
25
621
6305
—
13
23
617
6278
23
113
563
5853
25
146
384
4147
Leukocytes [#/volume] in Urine
30405-5 [3018095]
6.9e-01
6.6e-01
1.6e+00
—
1.4e+00
7.2e-01
3.2e-01
cases:19.59%
controls:10.88%
cases:12.95%
controls:7.14%
cases:3.63%
controls:0.74%
—
—
cases:4.13%
controls:1.03%
cases:13.65%
controls:7.16%
cases:23.72%
controls:18.45%
124
689
509
5641
82
452
551
5878
23
47
610
6283
—
26
65
604
6236
80
427
506
5539
97
792
312
3501
Other seropositive rheumatoid arthritis
M05.8 [45538634]
8.7e-01
1.2e+00
1.7e+00
—
1.8e+00
1.2e+00
9.4e-01
cases:3.32%
controls:1.42%
cases:3.79%
controls:1.12%
cases:1.58%
controls:0.28%
—
—
cases:0.95%
controls:0.16%
cases:3.58%
controls:1.09%
cases:3.91%
controls:1.56%
21
90
612
6240
24
71
609
6259
10
18
623
6312
—
6
10
624
6291
21
65
565
5901
16
67
393
4226
chloramphenicol
S03AA08 [21605197]
6.8e-01
1.1e+00
2.1e+00
—
7.0e-01
7.1e-01
5.2e-01
cases:17.38%
controls:9.62%
cases:9.48%
controls:3.48%
cases:3.16%
controls:0.41%
—
—
cases:0.79%
controls:0.40%
cases:7.68%
controls:3.92%
cases:18.34%
controls:11.81%
110
609
523
5721
60
220
573
6110
20
26
613
6304
—
5
25
625
6276
45
234
541
5732
75
507
334
3786
chloramphenicol
S01AA01 [21603554]
6.8e-01
1.1e+00
2.1e+00
—
7.0e-01
7.1e-01
5.2e-01
cases:17.38%
controls:9.62%
cases:9.48%
controls:3.48%
cases:3.16%
controls:0.41%
—
—
cases:0.79%
controls:0.40%
cases:7.68%
controls:3.92%
cases:18.34%
controls:11.81%
110
609
523
5721
60
220
573
6110
20
26
613
6304
—
5
25
625
6276
45
234
541
5732
75
507
334
3786
Heart failure, unspecified
I50.9 [45576879]
7.4e-01
1.0e+00
1.2e+00
—
1.6e+00
1.1e+00
6.4e-01
cases:6.48%
controls:3.21%
cases:5.53%
controls:2.12%
cases:1.42%
controls:0.43%
—
—
cases:2.22%
controls:0.48%
cases:6.83%
controls:2.35%
cases:10.76%
controls:5.99%
41
203
592
6127
35
134
598
6196
9
27
624
6303
—
14
30
616
6271
40
140
546
5826
44
257
365
4036
Bacterial infection, unspecified
A49.9 [45590816]
9.7e-01
1.6e+00
—
—
1.9e+00
1.6e+00
8.1e-01
cases:4.74%
controls:1.85%
cases:3.16%
controls:0.63%
—
—
—
—
cases:0.95%
controls:0.14%
cases:3.41%
controls:0.70%
cases:5.62%
controls:2.59%
30
117
603
6213
20
40
613
6290
—
—
6
9
624
6292
20
42
566
5924
23
111
386
4182
Herpes simplex facialis
B00.10 [2000500311]
2.6e+00
—
—
—
—
—
2.4e+00
cases:1.11%
controls:0.08%
—
—
—
—
—
—
—
—
—
—
cases:1.22%
controls:0.12%
7
5
626
6325
—
—
—
—
—
5
5
404
4288
CD4 cells/Lymphocytes in Specimen
80223-1 [21494815]
2.3e+00
—
—
—
—
—
2.7e+00
cases:1.11%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.14%
7
7
626
6323
—
—
—
—
—
8
6
401
4287
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
8.2e-01
9.8e-01
—
—
1.7e+00
7.3e-01
6.8e-01
cases:7.58%
controls:3.49%
cases:6.00%
controls:2.34%
—
—
—
—
cases:1.43%
controls:0.25%
cases:5.29%
controls:2.61%
cases:11.98%
controls:6.48%
48
221
585
6109
38
148
595
6182
—
—
9
16
621
6285
31
156
555
5810
49
278
360
4015
Malaise and fatigue
R53 [45553741]
8.5e-01
5.5e-01
2.2e+00
—
—
9.2e-01
9.0e-01
cases:9.48%
controls:4.27%
cases:3.48%
controls:2.04%
cases:1.74%
controls:0.19%
—
—
—
—
cases:5.46%
controls:2.25%
cases:14.91%
controls:6.66%
60
270
573
6060
22
129
611
6201
11
12
622
6318
—
—
32
134
554
5832
61
286
348
4007
Wegener granulomatosis
M31.3 [45591818]
2.3e+00
—
—
—
—
2.5e+00
2.4e+00
cases:0.79%
controls:0.08%
—
—
—
—
—
—
—
—
cases:1.02%
controls:0.08%
cases:1.22%
controls:0.12%
5
5
628
6325
—
—
—
—
6
5
580
5961
5
5
404
4288
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
5.3e-01
6.6e-01
1.2e+00
—
1.3e+00
6.7e-01
5.1e-01
cases:37.44%
controls:26.07%
cases:23.54%
controls:13.73%
cases:6.32%
controls:1.97%
—
—
cases:8.10%
controls:2.44%
cases:24.91%
controls:14.55%
cases:43.28%
controls:31.52%
237
1650
396
4680
149
869
484
5461
40
125
593
6205
—
51
154
579
6147
146
868
440
5098
177
1353
232
2940
Physiotherapy
R4110 [2001310233]
5.4e-01
7.9e-01
1.3e+00
—
2.2e+00
1.3e+00
4.6e-01
cases:11.37%
controls:6.94%
cases:5.37%
controls:2.51%
cases:0.95%
controls:0.27%
—
—
cases:3.02%
controls:0.33%
cases:6.48%
controls:1.94%
cases:9.05%
controls:5.92%
72
439
561
5891
34
159
599
6171
6
17
627
6313
—
19
21
611
6280
38
116
548
5850
37
254
372
4039
Osmolality of Urine
2695-5 [3026782]
6.1e-01
6.6e-01
1.7e+00
—
1.8e+00
5.3e-01
4.2e-01
cases:11.69%
controls:6.71%
cases:5.69%
controls:3.03%
cases:2.37%
controls:0.44%
—
—
cases:2.54%
controls:0.41%
cases:4.44%
controls:2.67%
cases:10.27%
controls:7.01%
74
425
559
5905
36
192
597
6138
15
28
618
6302
—
16
26
614
6275
26
159
560
5807
42
301
367
3992
Acute bronchitis, unspecified
J20.9 [45562445]
1.2e+00
1.3e+00
—
—
—
1.3e+00
9.5e-01
cases:8.69%
controls:2.69%
cases:3.16%
controls:0.92%
—
—
—
—
—
—
cases:2.90%
controls:0.79%
cases:7.33%
controls:2.96%
55
170
578
6160
20
58
613
6272
—
—
—
17
47
569
5919
30
127
379
4166
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
6.7e-01
9.0e-01
5.5e-01
—
1.8e+00
8.0e-01
6.2e-01
cases:7.90%
controls:4.22%
cases:6.32%
controls:2.67%
cases:0.79%
controls:0.46%
—
—
cases:1.59%
controls:0.27%
cases:6.31%
controls:2.95%
cases:13.45%
controls:7.71%
50
267
583
6063
40
169
593
6161
5
29
628
6301
—
10
17
620
6284
37
176
549
5790
55
331
354
3962
Neutrophil cytoplasmic Ab.perinuclear [Titer] in Serum by Immunofluorescence
14278-6 [3003284]
1.5e+00
1.1e+00
—
—
—
1.8e+00
1.5e+00
cases:2.21%
controls:0.52%
cases:0.79%
controls:0.25%
—
—
—
—
—
—
cases:1.19%
controls:0.20%
cases:2.44%
controls:0.56%
14
33
619
6297
5
16
628
6314
—
—
—
7
12
579
5954
10
24
399
4269
Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence
14277-8 [3004383]
1.5e+00
1.1e+00
—
—
—
1.8e+00
1.5e+00
cases:2.21%
controls:0.52%
cases:0.79%
controls:0.25%
—
—
—
—
—
—
cases:1.19%
controls:0.20%
cases:2.44%
controls:0.56%
14
33
619
6297
5
16
628
6314
—
—
—
7
12
579
5954
10
24
399
4269
Other chronic pain
R52.2 [45568139]
1.0e+00
2.4e+00
—
—
—
—
2.3e+00
cases:0.79%
controls:0.28%
cases:1.42%
controls:0.13%
—
—
—
—
—
—
—
—
cases:3.18%
controls:0.33%
5
18
628
6312
9
8
624
6322
—
—
—
—
13
14
396
4279
Myalgia
M79.1 [45587062]
8.3e-01
1.4e+00
2.5e+00
—
—
6.5e-01
7.1e-01
cases:4.74%
controls:2.12%
cases:2.37%
controls:0.60%
cases:0.95%
controls:0.08%
—
—
—
—
cases:1.37%
controls:0.72%
cases:4.40%
controls:2.21%
30
134
603
6196
15
38
618
6292
6
5
627
6325
—
—
8
43
578
5923
18
95
391
4198
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
4.7e-01
1.1e+00
1.0e+00
—
1.8e+00
1.1e+00
6.4e-01
cases:6.95%
controls:4.45%
cases:5.37%
controls:1.86%
cases:0.95%
controls:0.35%
—
—
cases:1.59%
controls:0.25%
cases:5.80%
controls:2.03%
cases:9.29%
controls:5.15%
44
282
589
6048
34
118
599
6212
6
22
627
6308
—
10
16
620
6285
34
121
552
5845
38
221
371
4072
Pain in limb
M79.6 [45587063]
9.2e-01
7.8e-01
4.1e-01
—
1.3e+00
7.8e-01
8.3e-01
cases:19.59%
controls:8.88%
cases:7.42%
controls:3.54%
cases:0.95%
controls:0.63%
—
—
cases:1.90%
controls:0.51%
cases:7.51%
controls:3.59%
cases:25.18%
controls:12.83%
124
562
509
5768
47
224
586
6106
6
40
627
6290
—
12
32
618
6269
44
214
542
5752
103
551
306
3742
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
2.2e-01
7.5e-01
1.3e+00
—
1.6e+00
1.0e+00
4.1e-01
cases:9.79%
controls:8.01%
cases:7.90%
controls:3.89%
cases:1.74%
controls:0.49%
—
—
cases:2.38%
controls:0.49%
cases:9.04%
controls:3.49%
cases:13.45%
controls:9.34%
62
507
571
5823
50
246
583
6084
11
31
622
6299
—
15
31
615
6270
53
208
533
5758
55
401
354
3892
Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection
50548-7 [3030692]
1.3e+00
2.3e+00
—
—
—
2.3e+00
—
cases:0.95%
controls:0.25%
cases:0.95%
controls:0.09%
—
—
—
—
—
—
cases:0.85%
controls:0.08%
—
—
6
16
627
6314
6
6
627
6324
—
—
—
5
5
581
5961
—
Skin symptom/complaint other
S29 [2002000993]
4.2e-01
1.2e+00
2.8e+00
—
1.6e+00
8.4e-01
6.7e-01
cases:6.00%
controls:4.03%
cases:3.63%
controls:1.17%
cases:1.26%
controls:0.08%
—
—
cases:0.79%
controls:0.16%
cases:3.41%
controls:1.51%
cases:9.05%
controls:4.82%
38
255
595
6075
23
74
610
6256
8
5
625
6325
—
5
10
625
6291
20
90
566
5876
37
207
372
4086
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
1.6e+00
1.7e+00
—
—
—
1.4e+00
8.5e-01
cases:5.69%
controls:1.23%
cases:3.00%
controls:0.58%
—
—
—
—
—
—
cases:2.22%
controls:0.57%
cases:2.69%
controls:1.16%
36
78
597
6252
19
37
614
6293
—
—
—
13
34
573
5932
11
50
398
4243
Treatment plan or consultation
WZC00 [2001310885]
6.5e-01
7.7e-01
1.6e+00
1.0e+50
—
8.1e-01
7.4e-01
cases:13.59%
controls:7.55%
cases:5.21%
controls:2.48%
cases:2.05%
controls:0.41%
cases:1.42%
controls:0.00%
—
—
cases:5.63%
controls:2.60%
cases:15.16%
controls:7.87%
86
478
547
5852
33
157
600
6173
13
26
620
6304
9
0
624
6330
—
33
155
553
5811
62
338
347
3955
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
8.0e-01
1.4e+00
—
—
—
1.5e+00
9.4e-01
cases:3.63%
controls:1.66%
cases:2.53%
controls:0.66%
—
—
—
—
—
—
cases:2.73%
controls:0.65%
cases:5.62%
controls:2.28%
23
105
610
6225
16
42
617
6288
—
—
—
16
39
570
5927
23
98
386
4195
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
6.6e-01
5.9e-01
1.5e+00
—
1.4e+00
9.8e-01
4.2e-01
cases:11.06%
controls:6.07%
cases:6.16%
controls:3.51%
cases:2.05%
controls:0.46%
—
—
cases:1.90%
controls:0.49%
cases:8.53%
controls:3.37%
cases:12.71%
controls:8.74%
70
384
563
5946
39
222
594
6108
13
29
620
6301
—
12
31
618
6270
50
201
536
5765
52
375
357
3918
Procalcitonin [Mass/volume] in Serum or Plasma
33959-8 [3046279]
1.4e+00
1.8e+00
—
—
2.3e+00
1.4e+00
2.0e-01
cases:2.84%
controls:0.73%
cases:1.90%
controls:0.33%
—
—
—
—
cases:0.79%
controls:0.08%
cases:2.56%
controls:0.67%
cases:1.96%
controls:1.61%
18
46
615
6284
12
21
621
6309
—
—
5
5
625
6296
15
40
571
5926
8
69
401
4224
filgrastim; parenteral
L03AA02 [21603851]
2.0e+00
2.5e+00
—
—
—
—
—
cases:2.05%
controls:0.28%
cases:0.95%
controls:0.08%
—
—
—
—
—
—
—
—
—
—
13
18
620
6312
6
5
627
6325
—
—
—
—
—
Limited function/disability (L)
L28 [2002000647]
5.7e-01
8.4e-01
9.6e-01
—
1.5e+00
9.7e-01
5.8e-01
cases:7.90%
controls:4.63%
cases:5.37%
controls:2.40%
cases:1.11%
controls:0.43%
—
—
cases:1.59%
controls:0.37%
cases:6.31%
controls:2.48%
cases:12.22%
controls:7.22%
50
293
583
6037
34
152
599
6178
7
27
626
6303
—
10
23
620
6278
37
148
549
5818
50
310
359
3983
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
1.3e+00
1.6e+00
—
—
—
—
1.5e+00
cases:3.79%
controls:1.04%
cases:1.74%
controls:0.35%
—
—
—
—
—
—
—
—
cases:3.42%
controls:0.79%
24
66
609
6264
11
22
622
6308
—
—
—
—
14
34
395
4259
Monoclonal gammopathy of undetermined significance (MGUS)
D47.2 [45566693]
2.1e+00
2.3e+00
—
—
—
—
—
cases:1.42%
controls:0.17%
cases:1.11%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
9
11
624
6319
7
7
626
6323
—
—
—
—
—
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
4.7e-01
6.4e-01
8.7e-01
—
1.3e+00
6.0e-01
5.4e-01
cases:36.65%
controls:26.60%
cases:23.54%
controls:14.00%
cases:4.90%
controls:2.12%
—
—
cases:7.30%
controls:2.13%
cases:23.21%
controls:14.20%
cases:44.25%
controls:31.73%
232
1684
401
4646
149
886
484
5444
31
134
602
6196
—
46
134
584
6167
136
847
450
5119
181
1362
228
2931
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
6.3e-01
1.4e+00
2.0e+00
—
—
1.0e+00
7.2e-01
cases:4.42%
controls:2.42%
cases:3.48%
controls:0.92%
cases:0.95%
controls:0.13%
—
—
—
—
cases:2.73%
controls:1.01%
cases:6.36%
controls:3.19%
28
153
605
6177
22
58
611
6272
6
8
627
6322
—
—
16
60
570
5906
26
137
383
4156
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
1.0e+00
2.1e+00
—
—
—
—
1.3e+00
cases:3.48%
controls:1.30%
cases:3.00%
controls:0.39%
—
—
—
—
—
—
—
—
cases:4.16%
controls:1.14%
22
82
611
6248
19
25
614
6305
—
—
—
—
17
49
392
4244
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
4.6e-01
1.5e+00
2.0e+00
—
—
7.5e-01
8.8e-01
cases:4.58%
controls:2.95%
cases:4.27%
controls:0.95%
cases:1.11%
controls:0.16%
—
—
—
—
cases:2.22%
controls:1.06%
cases:8.31%
controls:3.63%
29
187
604
6143
27
60
606
6270
7
10
626
6320
—
—
13
63
573
5903
34
156
375
4137
Lumbar and other intervertebral disc disorders with radiculopathy
M51.1 [45562747]
8.7e-01
1.8e+00
—
—
—
1.6e+00
1.0e+00
cases:3.00%
controls:1.28%
cases:1.58%
controls:0.25%
—
—
—
—
—
—
cases:1.54%
controls:0.30%
cases:3.18%
controls:1.16%
19
81
614
6249
10
16
623
6314
—
—
—
9
18
577
5948
13
50
396
4243
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
8.4e-01
1.5e+00
—
—
—
1.1e+00
9.1e-01
cases:6.16%
controls:2.76%
cases:2.69%
controls:0.62%
—
—
—
—
—
—
cases:2.73%
controls:0.92%
cases:7.82%
controls:3.31%
39
175
594
6155
17
39
616
6291
—
—
—
16
55
570
5911
32
142
377
4151
Implantation of vascular injection port
TPX10 [2001309608]
2.0e+00
2.3e+00
—
—
—
—
-1.0e+50
cases:1.26%
controls:0.17%
cases:0.95%
controls:0.09%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
8
11
625
6319
6
6
627
6324
—
—
—
—
0
7
409
4286
Cytomegalovirus IgG Ab [Titer] in Serum or Plasma
22246-3 [3017918]
1.5e+00
2.8e+00
—
—
—
—
—
cases:1.90%
controls:0.44%
cases:1.58%
controls:0.09%
—
—
—
—
—
—
—
—
—
—
12
28
621
6302
10
6
623
6324
—
—
—
—
—
Differential panel - Cerebral spinal fluid
29584-0 [3016018]
1.8e+00
2.5e+00
—
—
—
—
—
cases:1.42%
controls:0.24%
cases:0.95%
controls:0.08%
—
—
—
—
—
—
—
—
—
—
9
15
624
6315
6
5
627
6325
—
—
—
—
—
Demanding cystostatic therapy of methastized malignancy
WD125 [2001310680]
2.1e+00
2.2e+00
—
—
-1.0e+50
—
—
cases:2.53%
controls:0.33%
cases:1.90%
controls:0.21%
—
—
—
—
cases:0.00%
controls:0.08%
—
—
—
—
16
21
617
6309
12
13
621
6317
—
—
0
5
630
6296
—
—
Human bocavirus DNA [Presence] in Specimen by NAA with probe detection
62424-7 [40765161]
1.2e+00
2.0e+00
—
—
—
2.3e+00
1.2e+00
cases:1.26%
controls:0.38%
cases:1.11%
controls:0.16%
—
—
—
—
—
—
cases:1.19%
controls:0.12%
cases:1.22%
controls:0.37%
8
24
625
6306
7
10
626
6320
—
—
—
7
7
579
5959
5
16
404
4277
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
5.3e-01
6.1e-01
9.6e-01
—
1.5e+00
6.4e-01
3.1e-01
cases:28.44%
controls:18.94%
cases:14.22%
controls:8.23%
cases:2.53%
controls:0.98%
—
—
cases:3.65%
controls:0.86%
cases:15.19%
controls:8.62%
cases:27.38%
controls:21.66%
180
1199
453
5131
90
521
543
5809
16
62
617
6268
—
23
54
607
6247
89
514
497
5452
112
930
297
3363
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
1.1e+00
1.3e+00
1.6e+00
—
1.6e+00
1.0e+00
7.8e-01
cases:6.64%
controls:2.26%
cases:3.63%
controls:1.01%
cases:0.95%
controls:0.19%
—
—
cases:0.79%
controls:0.16%
cases:3.07%
controls:1.14%
cases:6.11%
controls:2.91%
42
143
591
6187
23
64
610
6266
6
12
627
6318
—
5
10
625
6291
18
68
568
5898
25
125
384
4168
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
8.4e-01
1.2e+00
—
—
—
1.1e+00
1.1e+00
cases:6.79%
controls:3.05%
cases:3.00%
controls:0.96%
—
—
—
—
—
—
cases:2.39%
controls:0.79%
cases:7.33%
controls:2.66%
43
193
590
6137
19
61
614
6269
—
—
—
14
47
572
5919
30
114
379
4179
General Surgery
2 [38004447]
6.1e-01
7.5e-01
1.0e+00
—
1.5e+00
6.7e-01
6.7e-01
cases:26.07%
controls:16.05%
cases:9.79%
controls:4.90%
cases:1.58%
controls:0.58%
—
—
cases:2.22%
controls:0.52%
cases:7.51%
controls:3.97%
cases:20.29%
controls:11.58%
165
1016
468
5314
62
310
571
6020
10
37
623
6293
—
14
33
616
6268
44
237
542
5729
83
497
326
3796
Chest pain, unspecified
R07.4 [45558450]
6.8e-01
9.9e-01
1.8e+00
—
1.4e+00
3.9e-01
6.2e-01
cases:12.16%
controls:6.57%
cases:5.06%
controls:1.94%
cases:1.58%
controls:0.25%
—
—
cases:0.79%
controls:0.21%
cases:2.90%
controls:1.98%
cases:11.25%
controls:6.38%
77
416
556
5914
32
123
601
6207
10
16
623
6314
—
5
13
625
6288
17
118
569
5848
46
274
363
4019
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
1.1e+00
1.3e+00
1.4e+00
—
1.4e+00
9.0e-01
8.2e-01
cases:5.06%
controls:1.82%
cases:4.42%
controls:1.22%
cases:0.79%
controls:0.19%
—
—
cases:0.79%
controls:0.19%
cases:4.10%
controls:1.71%
cases:7.09%
controls:3.26%
32
115
601
6215
28
77
605
6253
5
12
628
6318
—
5
12
625
6289
24
102
562
5864
29
140
380
4153
Other specified special examinations
Z01.8 [45581003]
8.8e-01
8.1e-01
2.3e+00
—
2.2e+00
1.0e+00
6.6e-01
cases:7.27%
controls:3.16%
cases:2.21%
controls:1.00%
cases:0.79%
controls:0.08%
—
—
cases:1.43%
controls:0.16%
cases:2.56%
controls:0.96%
cases:6.36%
controls:3.40%
46
200
587
6130
14
63
619
6267
5
5
628
6325
—
9
10
621
6291
15
57
571
5909
26
146
383
4147
Gout, unspecified
M10.9 [45543454]
1.0e+00
1.5e+00
—
—
—
1.6e+00
-1.6e-01
cases:3.48%
controls:1.26%
cases:1.90%
controls:0.44%
—
—
—
—
—
—
cases:2.39%
controls:0.50%
cases:1.47%
controls:1.72%
22
80
611
6250
12
28
621
6302
—
—
—
14
30
572
5936
6
74
403
4219
esomeprazole; oral, parenteral
A02BC05 [21600100]
7.6e-01
9.2e-01
1.0e+00
—
8.2e-01
7.9e-01
5.7e-01
cases:17.85%
controls:9.23%
cases:12.16%
controls:5.21%
cases:3.63%
controls:1.34%
—
—
cases:2.70%
controls:1.21%
cases:10.07%
controls:4.83%
cases:14.67%
controls:8.87%
113
584
520
5746
77
330
556
6000
23
85
610
6245
—
17
76
613
6225
59
288
527
5678
60
381
349
3912
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
9.5e-01
1.5e+00
—
—
—
1.6e+00
6.7e-01
cases:3.79%
controls:1.50%
cases:2.05%
controls:0.47%
—
—
—
—
—
—
cases:2.39%
controls:0.49%
cases:2.69%
controls:1.40%
24
95
609
6235
13
30
620
6300
—
—
—
14
29
572
5937
11
60
398
4233
ibuprofen
R02AX02 [1588667]
4.4e-01
7.7e-01
1.6e+00
—
1.2e+00
3.3e-01
1.3e-01
cases:40.28%
controls:30.25%
cases:23.70%
controls:12.59%
cases:8.37%
controls:1.82%
—
—
cases:5.08%
controls:1.57%
cases:15.87%
controls:11.97%
cases:28.36%
controls:25.74%
255
1915
378
4415
150
797
483
5533
53
115
580
6215
—
32
99
598
6202
93
714
493
5252
116
1105
293
3188
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
4.4e-01
7.7e-01
1.6e+00
—
1.2e+00
3.3e-01
1.3e-01
cases:40.28%
controls:30.25%
cases:23.70%
controls:12.59%
cases:8.37%
controls:1.82%
—
—
cases:5.08%
controls:1.57%
cases:15.87%
controls:11.97%
cases:28.36%
controls:25.74%
255
1915
378
4415
150
797
483
5533
53
115
580
6215
—
32
99
598
6202
93
714
493
5252
116
1105
293
3188
Paranasal sinuses X-ray examination in one projection
DM1QA [2001301761]
1.7e+00
2.3e+00
—
—
—
—
1.4e+00
cases:2.37%
controls:0.44%
cases:0.95%
controls:0.09%
—
—
—
—
—
—
—
—
cases:1.71%
controls:0.42%
15
28
618
6302
6
6
627
6324
—
—
—
—
7
18
402
4275
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
9.3e-01
1.4e+00
1.4e+00
—
1.4e+00
8.7e-01
8.0e-01
cases:4.27%
controls:1.72%
cases:4.42%
controls:1.18%
cases:0.79%
controls:0.19%
—
—
cases:0.79%
controls:0.19%
cases:3.92%
controls:1.68%
cases:6.60%
controls:3.07%
27
109
606
6221
28
75
605
6255
5
12
628
6318
—
5
12
625
6289
23
100
563
5866
27
132
382
4161
Paraesthesia of skin
R20.2 [45568120]
7.5e-01
1.9e+00
—
—
—
2.0e+00
1.0e+00
cases:1.42%
controls:0.68%
cases:1.26%
controls:0.19%
—
—
—
—
—
—
cases:1.02%
controls:0.13%
cases:1.71%
controls:0.61%
9
43
624
6287
8
12
625
6318
—
—
—
6
8
580
5958
7
26
402
4267
Lambda light chains.free [Mass/volume] in Serum or Plasma
33944-0 [3047169]
1.3e+00
1.3e+00
—
—
—
1.4e+00
1.0e+00
cases:3.32%
controls:0.95%
cases:1.74%
controls:0.49%
—
—
—
—
—
—
cases:2.05%
controls:0.52%
cases:2.69%
controls:1.00%
21
60
612
6270
11
31
622
6299
—
—
—
12
31
574
5935
11
43
398
4250
Dentistry
C5 [903277]
1.1e+00
1.6e+00
—
—
—
8.7e-01
1.2e+00
cases:5.53%
controls:1.86%
cases:3.16%
controls:0.63%
—
—
—
—
—
—
cases:1.71%
controls:0.72%
cases:6.60%
controls:2.17%
35
118
598
6212
20
40
613
6290
—
—
—
10
43
576
5923
27
93
382
4200
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
5.6e-01
9.2e-01
1.4e+00
—
2.1e+00
8.4e-01
5.9e-01
cases:4.90%
controls:2.84%
cases:3.95%
controls:1.61%
cases:1.11%
controls:0.27%
—
—
cases:1.59%
controls:0.19%
cases:3.58%
controls:1.58%
cases:9.78%
controls:5.66%
31
180
602
6150
25
102
608
6228
7
17
626
6313
—
10
12
620
6289
21
94
565
5872
40
243
369
4050
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
8.4e-01
8.0e-01
—
—
1.6e+00
5.4e-01
6.3e-01
cases:13.74%
controls:6.41%
cases:4.42%
controls:2.04%
—
—
—
—
cases:1.27%
controls:0.25%
cases:3.41%
controls:2.01%
cases:12.22%
controls:6.92%
87
406
546
5924
28
129
605
6201
—
—
8
16
622
6285
20
120
566
5846
50
297
359
3996
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
5.7e-01
7.1e-01
1.9e+00
—
2.9e+00
9.6e-01
6.2e-01
cases:5.69%
controls:3.29%
cases:2.84%
controls:1.42%
cases:0.95%
controls:0.14%
—
—
cases:1.75%
controls:0.10%
cases:3.58%
controls:1.41%
cases:6.60%
controls:3.66%
36
208
597
6122
18
90
615
6240
6
9
627
6321
—
11
6
619
6295
21
84
565
5882
27
157
382
4136
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
4.1e-01
6.4e-01
1.1e+00
—
1.2e+00
5.5e-01
3.3e-01
cases:22.75%
controls:16.38%
cases:16.90%
controls:9.67%
cases:3.63%
controls:1.28%
—
—
cases:5.08%
controls:1.57%
cases:17.41%
controls:10.83%
cases:33.01%
controls:26.25%
144
1037
489
5293
107
612
526
5718
23
81
610
6249
—
32
99
598
6202
102
646
484
5320
135
1127
274
3166
moxifloxacin; oral, parenteral
J01MA14 [21603021]
1.2e+00
1.6e+00
—
—
—
1.2e+00
1.1e+00
cases:3.16%
controls:0.98%
cases:1.74%
controls:0.35%
—
—
—
—
—
—
cases:1.02%
controls:0.32%
cases:3.42%
controls:1.21%
20
62
613
6268
11
22
622
6308
—
—
—
6
19
580
5947
14
52
395
4241
Diffusion capacity of lung
54715006 [4182985]
1.7e+00
2.2e+00
—
—
—
—
—
cases:1.74%
controls:0.32%
cases:0.95%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
11
20
622
6310
6
7
627
6323
—
—
—
—
—
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
3.7e-01
6.0e-01
1.1e+00
—
1.3e+00
5.5e-01
3.6e-01
cases:21.96%
controls:16.21%
cases:16.11%
controls:9.54%
cases:3.63%
controls:1.26%
—
—
cases:5.08%
controls:1.51%
cases:17.06%
controls:10.59%
cases:33.25%
controls:25.88%
139
1026
494
5304
102
604
531
5726
23
80
610
6250
—
32
95
598
6206
100
632
486
5334
136
1111
273
3182
Erysipelas
A46 [45561706]
6.6e-01
5.2e-01
3.2e+00
1.0e+50
—
5.5e-01
5.9e-01
cases:5.37%
controls:2.86%
cases:1.74%
controls:1.04%
cases:2.21%
controls:0.09%
cases:0.79%
controls:0.00%
—
—
cases:2.22%
controls:1.29%
cases:6.11%
controls:3.49%
34
181
599
6149
11
66
622
6264
14
6
619
6324
5
0
628
6330
—
13
77
573
5889
25
150
384
4143
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
1.1e+00
1.7e+00
—
—
—
—
1.0e+00
cases:5.37%
controls:1.94%
cases:3.79%
controls:0.70%
—
—
—
—
—
—
—
—
cases:5.62%
controls:2.05%
34
123
599
6207
24
44
609
6286
—
—
—
—
23
88
386
4205
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
3.8e-01
6.0e-01
1.1e+00
—
1.2e+00
5.3e-01
3.4e-01
cases:22.75%
controls:16.75%
cases:16.59%
controls:9.84%
cases:3.63%
controls:1.28%
—
—
cases:5.24%
controls:1.57%
cases:17.24%
controls:10.91%
cases:33.50%
controls:26.35%
144
1060
489
5270
105
623
528
5707
23
81
610
6249
—
33
99
597
6202
101
651
485
5315
137
1131
272
3162
nystatin
D01AA01 [21601911]
1.8e+00
2.0e+00
—
—
—
—
—
cases:2.37%
controls:0.39%
cases:1.26%
controls:0.17%
—
—
—
—
—
—
—
—
—
—
15
25
618
6305
8
11
625
6319
—
—
—
—
—
nystatin; vaginal
G01AA01 [21602363]
1.8e+00
2.0e+00
—
—
—
—
—
cases:2.37%
controls:0.39%
cases:1.26%
controls:0.17%
—
—
—
—
—
—
—
—
—
—
15
25
618
6305
8
11
625
6319
—
—
—
—
—
metronidazole and furazolidone
P01AB51 [45893518]
1.8e+00
2.0e+00
—
—
—
—
—
cases:2.37%
controls:0.39%
cases:1.26%
controls:0.17%
—
—
—
—
—
—
—
—
—
—
15
25
618
6305
8
11
625
6319
—
—
—
—
—
Counselling related to known health issue
SPAT1310 [2001700411]
4.6e-01
6.6e-01
1.7e+00
—
1.7e+00
3.9e-01
5.1e-01
cases:13.74%
controls:9.10%
cases:4.58%
controls:2.43%
cases:1.90%
controls:0.36%
—
—
cases:1.59%
controls:0.30%
cases:3.75%
controls:2.58%
cases:11.25%
controls:7.06%
87
576
546
5754
29
154
604
6176
12
23
621
6307
—
10
19
620
6282
22
154
564
5812
46
303
363
3990
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
5.4e-01
6.8e-01
9.7e-01
—
1.4e+00
7.4e-01
4.2e-01
cases:20.70%
controls:13.25%
cases:13.27%
controls:7.20%
cases:2.05%
controls:0.79%
—
—
cases:3.33%
controls:0.83%
cases:13.99%
controls:7.17%
cases:27.14%
controls:19.66%
131
839
502
5491
84
456
549
5874
13
50
620
6280
—
21
52
609
6249
82
428
504
5538
111
844
298
3449
pH of Venous blood
2746-6 [3012544]
5.1e-01
9.3e-01
1.4e+00
—
1.9e+00
9.6e-01
5.2e-01
cases:3.95%
controls:2.42%
cases:3.95%
controls:1.60%
cases:0.95%
controls:0.24%
—
—
cases:1.27%
controls:0.19%
cases:3.75%
controls:1.48%
cases:8.07%
controls:4.96%
25
153
608
6177
25
101
608
6229
6
15
627
6315
—
8
12
622
6289
22
88
564
5878
33
213
376
4080
Radiculopathy
M54.1 [45577287]
1.8e+00
2.0e+00
—
—
—
—
2.2e+00
cases:1.90%
controls:0.33%
cases:0.95%
controls:0.13%
—
—
—
—
—
—
—
—
cases:1.22%
controls:0.14%
12
21
621
6309
6
8
627
6322
—
—
—
—
5
6
404
4287
Cardiology
6 [38004451]
5.4e-01
7.4e-01
8.9e-01
—
1.1e+00
7.6e-01
6.4e-01
cases:25.75%
controls:16.81%
cases:15.80%
controls:8.18%
cases:2.84%
controls:1.18%
—
—
cases:3.33%
controls:1.17%
cases:14.68%
controls:7.48%
cases:27.87%
controls:16.86%
163
1064
470
5266
100
518
533
5812
18
75
615
6255
—
21
74
609
6227
86
446
500
5520
114
724
295
3569
Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
43730-1 [3043849]
1.5e+00
2.2e+00
—
—
—
—
1.3e+00
cases:2.05%
controls:0.46%
cases:1.58%
controls:0.17%
—
—
—
—
—
—
—
—
cases:1.22%
controls:0.35%
13
29
620
6301
10
11
623
6319
—
—
—
—
5
15
404
4278
triamcinolone and antiinfectives
S02CA04 [21605176]
1.7e+00
2.0e+00
—
—
—
—
—
cases:2.37%
controls:0.43%
cases:1.26%
controls:0.17%
—
—
—
—
—
—
—
—
—
—
15
27
618
6303
8
11
625
6319
—
—
—
—
—
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
5.2e-01
6.8e-01
9.0e-01
—
1.2e+00
7.1e-01
5.6e-01
cases:18.64%
controls:11.96%
cases:12.32%
controls:6.65%
cases:2.53%
controls:1.04%
—
—
cases:3.02%
controls:0.89%
cases:14.16%
controls:7.53%
cases:28.36%
controls:18.47%
118
757
515
5573
78
421
555
5909
16
66
617
6264
—
19
56
611
6245
83
449
503
5517
116
793
293
3500
Bacteria identified in Urine by Culture
630-4 [3026008]
4.9e-01
5.1e-01
1.1e+00
—
1.0e+00
5.3e-01
3.9e-01
cases:15.96%
controls:10.44%
cases:9.16%
controls:5.70%
cases:2.53%
controls:0.82%
—
—
cases:3.17%
controls:1.16%
cases:10.92%
controls:6.74%
cases:22.98%
controls:16.75%
101
661
532
5669
58
361
575
5969
16
52
617
6278
—
20
73
610
6228
64
402
522
5564
94
719
315
3574
Base excess in Venous blood by calculation
1927-3 [3002032]
5.1e-01
9.0e-01
1.1e+00
—
1.8e+00
1.0e+00
5.3e-01
cases:3.79%
controls:2.32%
cases:3.63%
controls:1.52%
cases:0.79%
controls:0.25%
—
—
cases:1.11%
controls:0.19%
cases:3.92%
controls:1.46%
cases:8.07%
controls:4.91%
24
147
609
6183
23
96
610
6234
5
16
628
6314
—
7
12
623
6289
23
87
563
5879
33
211
376
4082
Fever
A03 [2002000144]
7.7e-01
1.2e+00
—
—
—
1.7e+00
4.6e-01
cases:4.42%
controls:2.10%
cases:2.05%
controls:0.62%
—
—
—
—
—
—
cases:2.90%
controls:0.55%
cases:3.67%
controls:2.35%
28
133
605
6197
13
39
620
6291
—
—
—
17
33
569
5933
15
101
394
4192
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
9.5e-01
—
—
—
-1.0e+50
1.9e+00
1.7e+00
cases:1.58%
controls:0.62%
—
—
—
—
—
—
cases:0.00%
controls:0.08%
cases:1.37%
controls:0.20%
cases:2.20%
controls:0.40%
10
39
623
6291
—
—
—
0
5
630
6296
8
12
578
5954
9
17
400
4276
Abdominal ultrasound examination
JN3AE [2001305555]
1.1e+00
9.5e-01
—
—
—
1.3e+00
1.2e+00
cases:7.42%
controls:2.48%
cases:1.58%
controls:0.62%
—
—
—
—
—
—
cases:2.05%
controls:0.57%
cases:5.87%
controls:1.82%
47
157
586
6173
10
39
623
6291
—
—
—
12
34
574
5932
24
78
385
4215
salbutamol; inhalant
R03AC02 [21603256]
7.8e-01
8.1e-01
5.9e-01
—
8.9e-01
6.1e-01
5.7e-01
cases:30.17%
controls:16.56%
cases:16.90%
controls:8.26%
cases:2.84%
controls:1.60%
—
—
cases:3.17%
controls:1.33%
cases:15.02%
controls:8.78%
cases:28.12%
controls:18.12%
191
1048
442
5282
107
523
526
5807
18
101
615
6229
—
20
84
610
6217
88
524
498
5442
115
778
294
3515
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
1.1e+00
1.4e+00
1.6e+00
—
—
9.1e-01
1.1e+00
cases:5.85%
controls:2.02%
cases:3.48%
controls:0.87%
cases:0.79%
controls:0.16%
—
—
—
—
cases:2.22%
controls:0.91%
cases:5.87%
controls:1.96%
37
128
596
6202
22
55
611
6275
5
10
628
6320
—
—
13
54
573
5912
24
84
385
4209
doxycycline; oral, parenteral
J01AA02 [21602800]
8.2e-01
1.1e+00
1.1e+00
—
1.3e+00
1.0e+00
7.0e-01
cases:28.91%
controls:15.18%
cases:11.53%
controls:4.25%
cases:1.42%
controls:0.47%
—
—
cases:0.79%
controls:0.22%
cases:10.58%
controls:4.06%
cases:21.76%
controls:12.09%
183
961
450
5369
73
269
560
6061
9
30
624
6300
—
5
14
625
6287
62
242
524
5724
89
519
320
3774
fluconazole; oral, parenteral
J02AC01 [21603080]
6.8e-01
9.1e-01
—
—
2.0e+00
5.8e-01
6.4e-01
cases:8.69%
controls:4.58%
cases:3.16%
controls:1.30%
—
—
—
—
cases:1.43%
controls:0.19%
cases:2.22%
controls:1.26%
cases:6.85%
controls:3.73%
55
290
578
6040
20
82
613
6248
—
—
9
12
621
6289
13
75
573
5891
28
160
381
4133
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
7.1e-01
1.2e+00
1.4e+00
—
9.7e-01
1.1e+00
6.6e-01
cases:14.85%
controls:7.90%
cases:6.79%
controls:2.16%
cases:1.11%
controls:0.27%
—
—
cases:0.79%
controls:0.30%
cases:6.14%
controls:2.21%
cases:13.94%
controls:7.76%
94
500
539
5830
43
137
590
6193
7
17
626
6313
—
5
19
625
6282
36
132
550
5834
57
333
352
3960
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
5.3e-01
9.8e-01
1.4e+00
—
1.8e+00
7.9e-01
8.5e-01
cases:4.58%
controls:2.75%
cases:4.11%
controls:1.58%
cases:0.79%
controls:0.21%
—
—
cases:1.27%
controls:0.22%
cases:2.90%
controls:1.34%
cases:6.36%
controls:2.82%
29
174
604
6156
26
100
607
6230
5
13
628
6317
—
8
14
622
6287
17
80
569
5886
26
121
383
4172
Protein [Mass/volume] in Cerebral spinal fluid
2880-3 [3019473]
1.5e+00
2.1e+00
—
—
—
—
6.7e-01
cases:2.37%
controls:0.54%
cases:1.11%
controls:0.14%
—
—
—
—
—
—
—
—
cases:1.22%
controls:0.63%
15
34
618
6296
7
9
626
6321
—
—
—
—
5
27
404
4266
Cell count panel - Cerebral spinal fluid
34563-7 [3044290]
1.4e+00
2.2e+00
—
—
—
—
—
cases:1.90%
controls:0.47%
cases:0.95%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
12
30
621
6300
6
7
627
6323
—
—
—
—
—
Gas panel - Arterial blood
24336-0 [3019060]
7.5e-01
1.1e+00
—
—
—
1.5e+00
9.5e-01
cases:3.63%
controls:1.75%
cases:2.05%
controls:0.68%
—
—
—
—
—
—
cases:2.39%
controls:0.55%
cases:4.89%
controls:1.96%
23
111
610
6219
13
43
620
6287
—
—
—
14
33
572
5933
20
84
389
4209
Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]
1.8e-01
4.4e-01
2.0e+00
1.0e+50
1.6e+00
7.0e-01
4.0e-01
cases:6.95%
controls:5.88%
cases:3.79%
controls:2.48%
cases:1.58%
controls:0.22%
cases:0.95%
controls:0.00%
cases:1.43%
controls:0.30%
cases:4.44%
controls:2.26%
cases:7.33%
controls:5.05%
44
372
589
5958
24
157
609
6173
10
14
623
6316
6
0
627
6330
9
19
621
6282
26
135
560
5831
30
217
379
4076
Puncture of maxillary antrum
TDM10 [2001301819]
1.6e+00
—
—
—
—
—
1.9e+00
cases:1.42%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:1.71%
controls:0.26%
9
18
624
6312
—
—
—
—
—
7
11
402
4282
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
4.3e-01
7.1e-01
8.5e-01
—
1.3e+00
5.6e-01
4.8e-01
cases:16.11%
controls:11.14%
cases:10.43%
controls:5.42%
cases:2.05%
controls:0.88%
—
—
cases:2.22%
controls:0.60%
cases:9.22%
controls:5.50%
cases:20.54%
controls:13.79%
102
705
531
5625
66
343
567
5987
13
56
620
6274
—
14
38
616
6263
54
328
532
5638
84
592
325
3701
hydrocortisone buteprate
D07AB11 [21602115]
5.1e-01
6.5e-01
1.6e+00
—
1.1e+00
4.4e-01
6.6e-01
cases:13.27%
controls:8.45%
cases:5.85%
controls:3.14%
cases:1.74%
controls:0.35%
—
—
cases:0.79%
controls:0.27%
cases:4.44%
controls:2.92%
cases:13.94%
controls:7.71%
84
535
549
5795
37
199
596
6131
11
22
622
6308
—
5
17
625
6284
26
174
560
5792
57
331
352
3962
hydrocortisone butyrate
D07AB02 [21602106]
5.1e-01
6.5e-01
1.6e+00
—
1.1e+00
4.4e-01
6.6e-01
cases:13.27%
controls:8.45%
cases:5.85%
controls:3.14%
cases:1.74%
controls:0.35%
—
—
cases:0.79%
controls:0.27%
cases:4.44%
controls:2.92%
cases:13.94%
controls:7.71%
84
535
549
5795
37
199
596
6131
11
22
622
6308
—
5
17
625
6284
26
174
560
5792
57
331
352
3962
hydrocortisone aceponate
D07AC16 [21602135]
5.1e-01
6.5e-01
1.6e+00
—
1.1e+00
4.4e-01
6.6e-01
cases:13.27%
controls:8.45%
cases:5.85%
controls:3.14%
cases:1.74%
controls:0.35%
—
—
cases:0.79%
controls:0.27%
cases:4.44%
controls:2.92%
cases:13.94%
controls:7.71%
84
535
549
5795
37
199
596
6131
11
22
622
6308
—
5
17
625
6284
26
174
560
5792
57
331
352
3962
hydrocortisone
D07AA02 [21602102]
5.1e-01
6.5e-01
1.6e+00
—
1.1e+00
4.4e-01
6.6e-01
cases:13.27%
controls:8.45%
cases:5.85%
controls:3.14%
cases:1.74%
controls:0.35%
—
—
cases:0.79%
controls:0.27%
cases:4.44%
controls:2.92%
cases:13.94%
controls:7.71%
84
535
549
5795
37
199
596
6131
11
22
622
6308
—
5
17
625
6284
26
174
560
5792
57
331
352
3962
Neurosurgery
14 [38004459]
4.7e-01
1.1e+00
—
—
—
1.5e+00
8.8e-01
cases:3.95%
controls:2.51%
cases:2.53%
controls:0.87%
—
—
—
—
—
—
cases:3.75%
controls:0.89%
cases:5.62%
controls:2.42%
25
159
608
6171
16
55
617
6275
—
—
—
22
53
564
5913
23
104
386
4189
hydrocortisone
C05AA01 [21601608]
5.0e-01
6.4e-01
1.6e+00
—
1.1e+00
4.4e-01
6.6e-01
cases:13.27%
controls:8.50%
cases:5.85%
controls:3.16%
cases:1.74%
controls:0.35%
—
—
cases:0.79%
controls:0.27%
cases:4.44%
controls:2.92%
cases:13.94%
controls:7.73%
84
538
549
5792
37
200
596
6130
11
22
622
6308
—
5
17
625
6284
26
174
560
5792
57
332
352
3961
hydrocortisone
A07EA02 [21600654]
5.0e-01
6.4e-01
1.6e+00
—
1.1e+00
4.4e-01
6.6e-01
cases:13.27%
controls:8.50%
cases:5.85%
controls:3.16%
cases:1.74%
controls:0.35%
—
—
cases:0.79%
controls:0.27%
cases:4.44%
controls:2.92%
cases:13.94%
controls:7.73%
84
538
549
5792
37
200
596
6130
11
22
622
6308
—
5
17
625
6284
26
174
560
5792
57
332
352
3961
Oral Surgery
19 [38004464]
1.2e+00
2.2e+00
—
—
—
1.3e+00
1.1e+00
cases:2.84%
controls:0.90%
cases:1.74%
controls:0.19%
—
—
—
—
—
—
cases:1.02%
controls:0.27%
cases:2.44%
controls:0.82%
18
57
615
6273
11
12
622
6318
—
—
—
6
16
580
5950
10
35
399
4258
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
6.2e-01
9.3e-01
—
—
2.3e+00
1.1e+00
7.4e-01
cases:3.79%
controls:2.09%
cases:2.21%
controls:0.88%
—
—
—
—
cases:0.95%
controls:0.10%
cases:2.73%
controls:0.94%
cases:6.36%
controls:3.14%
24
132
609
6198
14
56
619
6274
—
—
6
6
624
6295
16
56
570
5910
26
135
383
4158
fusidic acid
D09AA02 [21602265]
6.6e-01
8.6e-01
1.9e+00
—
—
6.3e-01
5.5e-01
cases:7.90%
controls:4.23%
cases:3.48%
controls:1.50%
cases:1.42%
controls:0.22%
—
—
—
—
cases:2.90%
controls:1.56%
cases:8.80%
controls:5.26%
50
268
583
6062
22
95
611
6235
9
14
624
6316
—
—
17
93
569
5873
36
226
373
4067
fusidic acid; ointment
D06AX01 [21602062]
6.6e-01
8.6e-01
1.9e+00
—
—
6.3e-01
5.5e-01
cases:7.90%
controls:4.23%
cases:3.48%
controls:1.50%
cases:1.42%
controls:0.22%
—
—
—
—
cases:2.90%
controls:1.56%
cases:8.80%
controls:5.26%
50
268
583
6062
22
95
611
6235
9
14
624
6316
—
—
17
93
569
5873
36
226
373
4067
Mycobacterium sp identified in Specimen by Organism specific culture
543-9 [3005702]
1.4e+00
2.0e+00
—
—
—
1.6e+00
8.9e-01
cases:1.74%
controls:0.44%
cases:1.26%
controls:0.17%
—
—
—
—
—
—
cases:0.85%
controls:0.17%
cases:1.47%
controls:0.61%
11
28
622
6302
8
11
625
6319
—
—
—
5
10
581
5956
6
26
403
4267
Pain in joint
M25.5 [45586941]
6.7e-01
8.4e-01
—
—
1.4e+00
8.3e-01
1.0e+00
cases:9.95%
controls:5.37%
cases:3.63%
controls:1.60%
—
—
—
—
cases:0.79%
controls:0.19%
cases:3.58%
controls:1.59%
cases:14.43%
controls:5.68%
63
340
570
5990
23
101
610
6229
—
—
5
12
625
6289
21
95
565
5871
59
244
350
4049
Fungus identified in Specimen by Culture
580-1 [3000494]
6.7e-01
1.2e+00
—
—
—
1.4e+00
7.7e-01
cases:4.90%
controls:2.58%
cases:3.00%
controls:0.93%
—
—
—
—
—
—
cases:2.73%
controls:0.70%
cases:6.60%
controls:3.17%
31
163
602
6167
19
59
614
6271
—
—
—
16
42
570
5924
27
136
382
4157
epinephrine
S01EA01 [21603673]
8.8e-01
2.0e+00
—
—
—
—
1.3e+00
cases:1.74%
controls:0.73%
cases:1.26%
controls:0.17%
—
—
—
—
—
—
—
—
cases:2.69%
controls:0.72%
11
46
622
6284
8
11
625
6319
—
—
—
—
11
31
398
4262
epinephrine; parenteral
C01CA24 [21600303]
8.8e-01
2.0e+00
—
—
—
—
1.3e+00
cases:1.74%
controls:0.73%
cases:1.26%
controls:0.17%
—
—
—
—
—
—
—
—
cases:2.69%
controls:0.72%
11
46
622
6284
8
11
625
6319
—
—
—
—
11
31
398
4262
Hand Surgery
40 [38004480]
8.1e-01
1.2e+00
—
—
—
1.3e+00
9.2e-01
cases:4.58%
controls:2.10%
cases:2.21%
controls:0.68%
—
—
—
—
—
—
cases:2.22%
controls:0.60%
cases:4.16%
controls:1.70%
29
133
604
6197
14
43
619
6287
—
—
—
13
36
573
5930
17
73
392
4220
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
3.5e-01
5.9e-01
7.2e-01
—
1.7e+00
5.8e-01
4.8e-01
cases:18.01%
controls:13.35%
cases:9.32%
controls:5.37%
cases:1.26%
controls:0.62%
—
—
cases:2.38%
controls:0.46%
cases:8.19%
controls:4.78%
cases:20.54%
controls:13.74%
114
845
519
5485
59
340
574
5990
8
39
625
6291
—
15
29
615
6272
48
285
538
5681
84
590
325
3703
Dry eye syndrome
H04.10 [2000502254]
1.3e+00
1.1e+00
—
—
—
8.5e-01
9.4e-01
cases:4.58%
controls:1.34%
cases:2.37%
controls:0.79%
—
—
—
—
—
—
cases:2.05%
controls:0.89%
cases:5.62%
controls:2.28%
29
85
604
6245
15
50
618
6280
—
—
—
12
53
574
5913
23
98
386
4195
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
4.9e-01
1.1e+00
—
—
2.1e+00
1.4e+00
8.3e-01
cases:4.74%
controls:2.95%
cases:3.16%
controls:1.06%
—
—
—
—
cases:0.79%
controls:0.10%
cases:3.41%
controls:0.91%
cases:6.11%
controls:2.75%
30
187
603
6143
20
67
613
6263
—
—
5
6
625
6295
20
54
566
5912
25
118
384
4175
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
4.5e-01
6.9e-01
1.1e+00
—
1.4e+00
7.2e-01
4.5e-01
cases:13.27%
controls:8.91%
cases:7.58%
controls:3.97%
cases:1.58%
controls:0.55%
—
—
cases:1.90%
controls:0.46%
cases:8.36%
controls:4.26%
cases:15.89%
controls:10.74%
84
564
549
5766
48
251
585
6079
10
35
623
6295
—
12
29
618
6272
49
254
537
5712
65
461
344
3832
Acute maxillary sinusitis
J01.0 [45601112]
8.9e-01
1.2e+00
2.1e+00
—
—
9.2e-01
1.2e+00
cases:7.90%
controls:3.40%
cases:3.00%
controls:0.92%
cases:0.79%
controls:0.09%
—
—
—
—
cases:2.73%
controls:1.11%
cases:9.29%
controls:3.05%
50
215
583
6115
19
58
614
6272
5
6
628
6324
—
—
16
66
570
5900
38
131
371
4162
Neutrophil cytoplasmic Ab [Units/volume] in Serum
5128-4 [3001334]
1.2e+00
8.4e-01
—
—
—
2.1e+00
1.1e+00
cases:3.16%
controls:0.95%
cases:0.95%
controls:0.41%
—
—
—
—
—
—
cases:2.05%
controls:0.27%
cases:2.93%
controls:0.96%
20
60
613
6270
6
26
627
6304
—
—
—
12
16
574
5950
12
41
397
4252
Flank/axilla symptom/complaint
L05 [2002000630]
4.4e-01
2.0e+00
—
—
—
1.2e+00
1.3e+00
cases:1.42%
controls:0.92%
cases:1.58%
controls:0.22%
—
—
—
—
—
—
cases:1.02%
controls:0.30%
cases:4.16%
controls:1.19%
9
58
624
6272
10
14
623
6316
—
—
—
6
18
580
5948
17
51
392
4242
Shortness of breath/dyspnoea
R02 [2002000883]
8.3e-01
1.2e+00
-1.0e+50
—
—
1.2e+00
6.5e-01
cases:5.53%
controls:2.48%
cases:2.69%
controls:0.84%
cases:0.00%
controls:0.08%
—
—
—
—
cases:2.56%
controls:0.79%
cases:6.11%
controls:3.28%
35
157
598
6173
17
53
616
6277
0
5
633
6325
—
—
15
47
571
5919
25
141
384
4152
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
3.7e-01
5.1e-01
1.2e+00
—
1.1e+00
4.5e-01
4.0e-01
cases:18.01%
controls:13.18%
cases:10.90%
controls:6.87%
cases:3.16%
controls:0.93%
—
—
cases:2.38%
controls:0.81%
cases:8.87%
controls:5.87%
cases:24.94%
controls:18.17%
114
834
519
5496
69
435
564
5895
20
59
613
6271
—
15
51
615
6250
52
350
534
5616
102
780
307
3513
Inpatient Visit
IP [9201]
4.3e-01
5.1e-01
6.0e-01
—
1.6e+00
7.5e-01
4.6e-01
cases:13.90%
controls:9.49%
cases:6.95%
controls:4.31%
cases:1.26%
controls:0.70%
—
—
cases:2.22%
controls:0.48%
cases:8.70%
controls:4.32%
cases:18.58%
controls:12.58%
88
601
545
5729
44
273
589
6057
8
44
625
6286
—
14
30
616
6271
51
258
535
5708
76
540
333
3753
dexamethasone and antiinfectives
S02CA06 [21605178]
1.5e+00
1.7e+00
—
—
—
—
-7.3e-03
cases:2.69%
controls:0.60%
cases:1.58%
controls:0.30%
—
—
—
—
—
—
—
—
cases:1.71%
controls:1.72%
17
38
616
6292
10
19
623
6311
—
—
—
—
7
74
402
4219
Trochanteric bursitis
M70.6 [45606304]
8.0e-01
1.3e+00
—
—
—
-2.4e-02
1.0e+00
cases:6.00%
controls:2.80%
cases:2.69%
controls:0.71%
—
—
—
—
—
—
cases:1.19%
controls:1.22%
cases:7.09%
controls:2.63%
38
177
595
6153
17
45
616
6285
—
—
—
7
73
579
5893
29
113
380
4180

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
127
401
3.71
34.37
3.8
2.9
9.48
10.99
g/l
2.06
119
361
420
2668
2.71
30.61
7.6
4.8
34.65
34.87
g/l
0.33
397
2492
318
1826
2.49
27.76
10.2
5.7
—
—
—
0
0
415
2736
2.50
26.10
10.4
5.8
0.04
0.04
e9/l
0.74
375
2306
446
3045
2.57
25.91
10.6
6.6
1.21
1.21
mmol/l
0.14
387
2623
549
4169
3.39
25.83
12.9
8.1
77.15
80.86
u/l
1.29
538
3928
421
2807
2.49
25.62
11.0
6.0
0.19
0.19
e9/l
0.23
388
2396
304
1756
2.41
25.60
6.3
4.2
—
—
—
0
0
394
2553
2.44
25.51
11.0
6.0
25.58
26.19
%
0.45
380
2412
418
2782
2.48
25.47
10.6
5.8
1.89
1.87
e9/l
0.05
386
2404
412
2725
2.47
25.45
10.4
5.8
0.63
0.60
e9/l
1.43
374
2292
389
2513
2.42
25.26
11.2
6.0
8.93
9.04
%
0.31
375
2344
448
3085
2.55
25.21
14.4
9.5
4.53
4.23
e9/l
1.55
406
2653
414
2752
2.46
25.16
8.4
6.0
1.20
1.21
mmol/l
1.06
386
2515
151
631
2.83
24.99
1.7
1.6
—
—
—
0
0
387
2508
2.40
24.74
11.0
5.9
2.69
2.79
%
0.35
373
2336
437
2989
2.49
24.73
8.5
6.6
11.03
12.27
umol/l
1.91
430
2848
388
2521
2.39
24.61
10.6
5.8
59.49
58.63
%
0.65
375
2393
306
1805
2.35
24.16
2.9
2.2
268.60
246.29
u/l
0.11
288
1704
384
2507
2.35
23.75
11.3
6.0
0.63
0.66
%
0.42
370
2333
378
2452
2.34
23.72
4.0
2.9
253.30
128.42
ug/l
1.21
351
2250
469
3349
2.55
23.57
7.4
4.9
6.75
6.73
mmol/l
0.05
458
3187
195
957
2.50
23.13
3.3
2.3
2.33
2.29
g/l
0.56
186
893
185
890
2.52
22.87
3.3
2.3
23.68
21.39
%
0.46
179
836
28
35
8.32
21.04
2.7
1.7
31.03
39.45
%
1.32
28
35
91
315
3.21
20.82
3.1
1.6
1.36
1.36
g/l
0.00
81
279
59
156
4.07
20.21
1.7
1.6
0.22
0.23
g/l
0.18
53
151
40
77
5.48
20.10
2.6
2.5
—
—
—
0
0
372
2503
2.18
19.95
3.1
2.4
80.59
79.43
nmol/l
0.33
342
2211
123
515
2.72
19.93
3.5
2.5
65.32
66.19
g/l
0.57
112
471
407
2843
2.21
19.77
22.5
18.1
1.29
1.34
inr
0.98
358
2386
495
3757
2.46
19.56
7.2
4.8
—
2.82
—
0
8
282
1743
2.11
18.42
3.4
2.4
54.54
64.54
u/l
1.58
263
1606
320
2083
2.08
18.10
4.7
3.2
1879.42
1510.68
ng/l
0.76
291
1819
214
1199
2.19
17.92
2.1
1.6
1.12
1.45
mg/l
1.49
178
950
264
1609
2.10
17.73
2.9
2.3
3.01
3.01
mg/l
0.01
229
1376
140
667
2.41
17.15
2.0
1.6
—
—
—
0
0
291
1870
2.03
16.63
6.0
3.9
7.40
7.40
ph
0.09
219
1341
101
423
2.65
16.18
3.6
2.3
—
—
—
0
0
26
41
6.57
15.94
1.3
1.2
—
—
—
0
0
505
4003
2.29
15.84
4.9
4.3
15.26
15.04
pmol/l
1.16
473
3611
134
649
2.35
15.70
1.5
1.3
909.09
479.46
titre
1.33
33
148
132
637
2.35
15.59
4.0
3.3
3.72
4.84
e9/l
1.83
112
539
111
498
2.49
15.39
2.8
1.9
350.03
404.81
nmol/l
1.77
106
461
177
970
2.14
15.32
1.9
1.4
2.13
2.67
g/l
2.94
117
544
333
2289
1.96
15.26
6.4
4.1
40.37
80.30
ng/l
0.83
265
1756
78
295
2.88
15.15
1.2
1.4
—
—
—
0
0
429
3223
2.03
15.10
4.1
3.2
58.52
51.99
u/l
0.66
402
2971
146
747
2.24
14.97
5.1
2.4
1.93
1.84
%
0.35
134
667
375
2697
1.96
14.89
2.6
2.2
93.05
95.32
pmol/l
0.41
216
1393
228
1388
2.00
14.76
4.2
2.7
4.55
5.55
e6/l
1.09
210
1266
103
457
2.50
14.58
1.7
1.5
—
—
—
0
0
227
1387
1.99
14.49
4.6
2.8
341.76
354.34
umol/l
1.00
202
1197
175
977
2.09
14.30
4.9
3.1
0.80
0.82
mmol/l
1.91
164
912
152
804
2.17
14.29
8.9
4.7
1.06
1.03
mmol/l
0.52
142
734
27
50
5.60
14.12
1.3
1.1
—
—
—
0
0
105
480
2.42
13.91
6.7
4.4
0.30
0.57
%
1.20
50
149
250
1608
1.92
13.51
5.2
3.4
—
0.00
estimate
—
0
10
44
126
3.68
13.45
4.4
4.0
—
—
—
0
0
391
2912
1.90
13.30
5.8
4.3
0.00
0.00
estimate
-0.00
90
634
119
588
2.26
13.14
5.8
2.5
74.51
70.97
e9/l
0.33
88
430
394
2949
1.89
13.11
5.9
4.3
17.19
5.33
estimate
0.30
90
657
108
515
2.32
12.96
6.9
4.3
0.47
0.84
%
1.88
54
167
308
2140
1.86
12.92
3.9
3.5
2.36
2.36
mmol/l
0.21
285
1922
254
1662
1.88
12.88
10.4
6.2
—
—
—
0
0
394
2968
1.87
12.64
6.0
4.3
0.00
0.49
estimate
0.52
83
623
145
793
2.07
12.32
1.3
1.3
5.98
15.49
u/ml
1.88
52
281
315
2228
1.82
12.26
6.4
4.2
64.70
143.04
e6/l
1.31
245
1608
102
486
2.31
12.23
7.1
4.4
0.08
0.08
%
0.02
48
137
288
1985
1.83
12.18
5.7
3.5
30.30
66.74
e6/l
2.01
243
1542
294
2042
1.82
12.10
4.5
3.5
—
—
—
0
0
57
205
2.96
12.09
4.7
3.5
118.49
84.63
mg/l
0.21
49
173
57
205
2.96
12.09
4.7
3.5
47.03
68.20
mg/l
0.44
50
176
153
863
2.02
11.91
1.4
1.3
59.85
37.67
iu/ml
0.47
44
271
196
1205
1.91
11.86
7.0
4.3
669.27
320.94
ng/l
0.59
173
1022
582
5094
2.77
11.70
37.2
17.8
24.18
26.34
mg/l
0.86
543
4274
254
1703
1.82
11.62
5.4
3.4
0.42
0.51
e6/l
0.26
204
1273
111
564
2.17
11.35
1.6
1.5
—
—
—
0
0
31
78
4.13
11.33
1.4
1.3
—
—
—
0
0
272
1873
1.79
11.31
2.0
1.8
20.26
20.35
nmol/l
0.03
239
1572
54
198
2.89
11.06
2.1
1.2
—
—
—
0
0
35
98
3.72
11.05
1.3
1.2
—
—
—
0
0
52
188
2.92
10.93
4.6
3.2
15.82
2.91
ratio
0.60
36
102
322
2346
1.76
10.89
4.6
3.8
6.36
6.26
ph
0.79
180
1279
161
952
1.93
10.82
2.4
1.9
29.90
29.53
s
0.34
155
921
17
12
14.52
10.53
2.3
1.5
38.18
28.42
%
0.79
17
12
337
2504
1.74
10.49
3.7
2.7
—
—
estimate
—
0
0
247
1694
1.75
10.13
4.4
3.2
32.39
33.89
u/l
0.16
238
1599
258
1807
1.72
9.72
3.4
2.4
—
—
—
0
0
550
4788
2.13
9.61
6.7
5.4
1.93
2.02
mu/l
0.90
523
4339
67
295
2.42
9.55
1.7
1.7
1.40
1.60
g/l
0.84
58
265
40
135
3.10
9.48
1.6
1.6
—
—
—
0
0
36
115
3.26
9.33
1.2
1.3
17.21
11.40
e6/l
0.26
28
80
36
116
3.23
9.21
1.3
1.3
64.07
1209.60
e6/l
0.57
28
85
112
616
1.99
9.18
3.7
2.9
6.77
8.73
umol/l
1.05
99
544
20
42
4.88
9.12
1.8
1.2
—
—
—
0
0
169
1067
1.80
9.04
4.5
3.1
1.50
1.25
e6/l
0.34
108
574
62
273
2.41
8.83
1.6
1.3
566.00
170.63
u/ml
0.70
55
250
118
672
1.93
8.72
4.5
3.2
2.69
1.89
mmol/l
1.66
109
568
589
5316
2.55
8.71
40.3
21.9
4.01
3.99
mmol/l
0.91
584
5190
174
1119
1.77
8.70
7.3
4.8
—
—
—
0
0
23
57
4.15
8.59
1.4
1.7
—
—
—
0
0
130
768
1.87
8.58
6.4
6.8
7.42
7.42
ph
0.21
83
440
588
5311
2.51
8.53
39.9
21.8
139.27
139.61
mmol/l
2.19
583
5197
186
1226
1.73
8.50
4.0
3.1
466.51
531.67
mosm/kgh2o
4.65
167
1071
102
557
1.99
8.50
2.9
2.5
30.08
32.46
u/l
0.42
90
459
129
763
1.87
8.47
6.6
6.8
2.42
1.08
mmol/l
3.52
112
630
119
687
1.90
8.42
4.7
3.2
7.37
7.38
ph
0.75
70
399
38
135
2.93
8.26
1.5
1.3
56.58
58.12
mmol/l
0.11
33
109
93
497
2.02
8.22
8.1
4.8
0.10
0.10
%
0.01
39
131
136
830
1.81
8.05
2.5
1.9
—
—
—
0
0
291
2181
1.62
8.00
5.7
4.3
0.34
0.04
estimate
0.45
77
516
98
539
1.97
7.98
3.4
2.5
5.27
6.51
ug/l
0.30
89
465
100
558
1.94
7.81
4.6
7.5
—
—
—
0
0
315
2417
1.60
7.79
21.4
11.7
0.00
0.00
e9/l
0.16
273
1962
548
4856
1.96
7.73
7.9
6.8
40.86
39.72
mmol/mol
1.94
507
4500
48
200
2.51
7.70
2.0
1.7
9.16
6.43
iu/ml
—
9
48
587
5338
2.37
7.67
20.6
12.4
23.86
24.20
u/l
0.23
580
5160
113
664
1.85
7.53
1.9
1.4
—
—
—
0
0
76
392
2.07
7.39
7.2
3.5
7.42
7.42
ph
0.03
68
326
13
12
11.03
7.32
1.2
1.3
—
—
—
0
0
591
5409
2.40
7.27
44.3
24.0
87.15
80.33
umol/l
2.93
586
5331
95
534
1.92
7.24
3.0
2.1
0.00
0.03
estimate
0.50
14
108
36
134
2.79
7.21
1.8
2.2
11.53
13.10
mg/l
0.50
31
123
24
70
3.52
7.18
1.3
1.3
123.06
171.57
au/ml
—
5
20
50
220
2.38
7.15
3.3
2.0
9.99
10.65
g/l
0.45
42
193
87
478
1.95
7.09
4.4
3.4
98.07
87.29
ng/l
0.63
76
408
100
579
1.86
6.95
2.9
2.2
137.65
137.79
ug/g
0.00
83
453
165
1104
1.67
6.95
1.3
1.2
0.69
1.56
u/ml
2.35
37
280
448
3792
1.62
6.94
5.8
4.5
—
0.45
—
0
11
63
311
2.14
6.86
1.3
1.3
—
—
—
0
0
185
1280
1.63
6.81
6.0
4.6
1.02
1.02
kg/l
0.79
129
858
21
58
3.71
6.80
1.8
1.2
—
—
—
0
0
97
562
1.86
6.73
2.1
2.2
0.20
0.20
g/l
0.11
90
517
20
54
3.79
6.68
1.3
1.0
—
—
—
0
0
95
548
1.86
6.68
7.3
4.1
7.38
7.36
ph
1.05
69
378
119
738
1.75
6.59
1.3
1.2
—
—
—
0
0
77
416
1.97
6.58
10.3
6.2
25.46
24.37
mmol/l
1.62
77
399
184
1281
1.62
6.58
1.8
1.8
453.42
5736578.39
pmol/l
0.50
155
1046
171
1173
1.63
6.48
1.9
1.8
1133.81
1229.20
nmol/l
0.76
135
878
44
192
2.39
6.42
1.2
1.2
0.30
2.53
u/ml
—
6
11
150
998
1.66
6.40
4.9
3.3
1.61
2.66
e6/l
1.15
88
501
274
2105
1.53
6.31
2.4
2.3
—
—
—
0
0
256
1940
1.54
6.27
4.4
3.3
6.89
7.07
mmol/l
0.28
215
1619
553
4992
1.85
6.27
6.3
5.5
6.06
6.00
mmol/l
0.44
512
4505
14
20
7.13
6.24
1.1
1.2
—
—
—
0
0
72
390
1.95
6.11
3.2
3.3
24.27
24.14
mmol/l
0.13
72
385
251
1907
1.52
6.01
3.9
3.3
54.93
45.36
mg/l
0.35
169
1226
53
258
2.15
5.99
1.8
1.5
—
—
—
0
0
224
1662
1.54
5.98
6.4
4.4
0.00
0.00
estimate
0.50
80
576
103
631
1.76
5.92
7.3
7.5
115.21
119.68
g/l
1.60
103
617
100
610
1.76
5.83
1.3
1.3
—
—
—
0
0
590
5471
2.15
5.76
51.1
27.3
239.81
244.93
e9/l
0.98
581
5353
590
5473
2.15
5.72
50.9
27.3
7.28
6.83
e9/l
1.15
580
5334
590
5473
2.15
5.72
50.9
27.2
4.29
4.39
e12/l
4.87
581
5334
567
5196
1.87
5.59
30.0
16.2
—
—
—
0
0
91
547
1.78
5.58
3.8
3.2
302.20
245.81
ng/l
0.43
86
513
27
100
2.78
5.50
3.1
2.3
—
—
—
0
0
19
57
3.41
5.48
2.1
1.3
19.02
28.71
ng/l
0.75
19
57
86
513
1.78
5.41
3.1
2.6
0.38
0.68
e6/l
0.72
81
491
184
1339
1.53
5.25
3.3
3.1
2.47
2.46
mmol/l
0.49
164
1210
22
75
3.00
5.19
1.0
1.0
—
—
—
0
0
75
435
1.82
5.17
4.0
3.0
6.17
6.13
ph
0.13
60
302
251
1956
1.47
5.10
4.6
3.9
11.11
7.86
mg/mmol
0.46
163
1215
17
50
3.47
5.06
1.2
1.1
—
—
—
0
0
39
180
2.24
5.05
4.0
3.5
0.96
0.83
nmol/l
0.77
32
151
17
51
3.40
4.91
1.6
1.2
—
—
—
0
0
541
4932
1.67
4.90
5.9
5.1
1.44
1.47
mmol/l
0.93
500
4493
522
4729
1.59
4.71
5.0
4.3
1.38
1.26
mmol/l
3.54
476
4248
51
269
1.97
4.69
2.0
2.1
—
—
—
0
0
543
4968
1.65
4.69
6.0
5.2
4.48
4.51
mmol/l
0.32
504
4552
30
128
2.41
4.65
5.2
4.0
—
—
—
0
0
17
53
3.27
4.64
1.2
1.3
—
—
—
0
0
552
5081
1.68
4.53
6.8
6.1
2.51
2.59
mmol/l
1.31
515
4640
33
149
2.28
4.51
3.6
2.3
118.96
125.80
g/l
0.85
26
113
39
189
2.13
4.50
2.0
1.8
20.84
20.90
s
0.03
32
177
16
49
3.32
4.49
1.4
1.1
—
—
—
0
0
19
65
2.98
4.47
1.6
2.2
0.46
0.99
g/24h
—
10
34
12
23
5.30
4.47
2.3
3.6
796.75
986.96
u/ml
0.30
12
23
18
60
3.06
4.43
1.2
1.1
—
—
—
0
0
21
77
2.79
4.39
9.2
2.0
32.57
31.88
pg
0.23
21
77
93
601
1.64
4.37
2.6
2.7
4.32
4.32
kpa
0.01
93
578
16
50
3.26
4.36
1.0
1.1
—
—
—
0
0
51
277
1.91
4.33
7.3
3.5
—
—
—
0
0
15
39
3.91
4.22
1.0
1.3
—
—
—
0
0
21
79
2.72
4.19
1.7
1.4
—
—
—
0
0
21
79
2.72
4.19
1.7
1.4
—
—
—
0
0
21
79
2.72
4.19
1.7
1.4
—
—
—
0
0
21
79
2.72
4.19
1.7
1.4
—
—
—
0
0
49
269
1.89
4.04
1.5
1.2
—
—
—
0
0
30
137
2.25
4.02
1.4
1.3
3644.21
21845.00
e6/l
2.52
19
90
22
88
2.55
3.92
1.3
1.2
9.95
11.71
u/l
0.25
17
70
11
23
4.85
3.88
1.2
1.5
—
—
—
0
0
63
379
1.74
3.87
1.1
1.1
—
—
—
0
0
8
11
7.35
3.87
1.5
1.3
—
—
—
0
0
26
115
2.31
3.76
3.9
4.8
3.44
2.69
mmol/l
0.55
20
74
76
485
1.64
3.76
7.1
3.7
1.22
1.22
mmol/l
0.15
67
417
12
30
4.06
3.61
1.2
2.0
—
—
—
0
0
27
124
2.23
3.59
1.6
1.4
34.67
29.23
iu/l
0.26
21
108
10
21
4.82
3.56
1.4
1.0
2472.00
1678.00
miu/ml
—
10
21
11
27
4.13
3.41
1.3
1.2
—
—
—
0
0
7
10
7.06
3.37
1.0
1.0
—
—
—
0
0
24
108
2.27
3.36
5.6
2.6
8.16
9.01
pmol/l
0.21
24
108
20
83
2.46
3.33
3.9
3.1
4.07
4.38
e9/l
0.35
20
83
33
170
1.99
3.30
2.5
2.4
56.20
58.24
%
0.21
33
165
75
498
1.57
3.17
1.6
1.4
—
—
—
0
0
19
79
2.45
3.16
1.3
1.1
416.33
300.93
u/ml
0.41
12
42
23
105
2.24
3.13
1.4
1.2
—
—
—
0
0
18
77
2.38
2.84
1.1
1.0
—
—
—
0
0
205
1672
1.33
2.83
5.8
5.9
2.45
3.24
ug/l
0.64
179
1489
37
210
1.81
2.81
8.0
4.0
24.55
25.07
mmol/l
0.41
32
193
30
159
1.93
2.80
4.4
3.5
1.08
1.82
index
0.44
12
78
32
174
1.88
2.78
1.3
1.2
—
—
—
0
0
45
272
1.70
2.77
2.7
2.1
0.00
0.01
estimate
0.49
13
85
20
91
2.24
2.76
8.7
2.2
0.90
0.89
%
0.03
13
62
6
10
6.04
2.70
1.2
1.5
—
—
—
0
0
49
306
1.65
2.68
2.4
2.4
—
—
—
0
0
15
61
2.49
2.63
1.0
1.1
—
18.92
—
0
16
44
270
1.68
2.57
1.3
1.3
—
—
—
0
0
12
44
2.76
2.56
1.0
1.2
126.67
100.93
pmol/l
0.88
12
44
12
42
2.89
2.56
1.6
1.2
—
—
—
0
0
13
50
2.63
2.54
1.2
1.3
—
—
—
0
0
0
65
0.00
2.43
0.0
1.1
—
—
—
0
0
6
12
5.04
2.40
2.0
2.5
—
—
—
0
0
48
310
1.59
2.32
3.6
3.9
1.02
1.02
ratio
0.57
42
283
8
23
3.51
2.27
2.5
2.7
0.61
0.61
mmol/l
—
8
23
23
121
1.93
2.23
11.7
6.4
10.96
11.25
mmol/l
0.17
23
107
23
121
1.93
2.23
11.7
6.4
106.13
105.11
mmol/l
0.63
23
107
21
107
2.00
2.23
1.3
1.3
—
—
—
0
0
16
73
2.22
2.22
1.5
1.5
—
—
—
0
0
5
9
5.59
2.21
1.0
1.0
—
—
—
0
0
24
130
1.88
2.15
1.1
1.2
—
—
—
0
0
5
10
5.03
2.07
4.6
2.5
—
—
—
0
0
7
20
3.53
2.06
1.4
1.4
—
—
—
0
0
13
56
2.35
2.06
2.4
2.1
2273.56
4886.37
u/l
—
8
19
10
38
2.66
2.01
1.0
1.1
—
—
—
0
0
24
136
1.79
1.90
1.1
1.2
—
73.12
—
0
16
29
174
1.70
1.89
1.0
1.5
0.32
0.30
mg/l
0.08
14
75
7
22
3.21
1.88
1.0
1.1
—
—
—
0
0
7
22
3.21
1.88
1.0
1.1
—
—
—
0
0
9
34
2.67
1.87
3.9
1.5
73.56
78.70
ng/l
—
9
34
21
115
1.85
1.85
5.0
2.9
59.24
59.07
%
0.02
21
115
241
2100
1.24
1.84
2.1
1.9
1.36
1.29
mmol/l
0.70
201
1734
5
12
4.19
1.82
1.6
1.7
6.70
9.00
mmol/l
—
5
12
12
53
2.29
1.81
1.3
1.9
851.35
1215.57
mg
0.21
12
53
51
355
1.47
1.81
2.6
2.3
12.28
12.88
nmol/l
0.15
38
310
33
208
1.62
1.80
3.8
3.1
265.60
245.09
mg/l
0.11
15
82
23
131
1.78
1.80
1.2
1.1
—
—
—
0
0
59
424
1.43
1.78
1.7
1.5
—
—
—
0
0
18
95
1.92
1.77
1.3
1.2
—
—
—
0
0
6
18
3.35
1.75
1.3
1.4
124.33
141.06
nmol/l
—
6
18
7
24
2.94
1.72
1.4
1.2
132.73
167.97
pmol/l
—
7
24
5
13
3.87
1.72
1.0
1.2
60.60
74.46
nmol/24h
—
5
13
178
1514
1.24
1.67
5.1
3.8
0.00
0.06
estimate
0.60
75
489
8
31
2.60
1.66
1.0
1.0
—
—
—
0
0
28
175
1.63
1.60
1.3
1.4
290.23
265.82
ug/g
0.28
17
96
8
32
2.52
1.60
2.0
1.4
83.75
79.34
umol/l
—
8
32
7
156
0.44
1.57
1.0
1.4
—
—
—
0
0
59
438
1.38
1.51
6.2
4.1
—
—
—
0
0
5
16
3.14
1.44
2.6
1.7
1.64
1.38
nmol/l
—
5
11
6
22
2.74
1.43
1.2
1.3
9.33
33.20
%
—
6
17
28
181
1.57
1.42
1.5
1.6
53.58
19.10
u/ml
—
6
29
11
53
2.09
1.39
1.0
1.1
—
—
—
0
0
36
249
1.47
1.36
2.2
2.8
—
—
—
0
0
6
24
2.51
1.30
1.2
1.0
—
—
—
0
0
5
18
2.79
1.28
1.0
2.2
—
—
—
0
0
10
48
2.10
1.28
1.7
2.0
—
—
—
0
0
23
146
1.60
1.27
1.1
1.2
—
880.00
—
0
5
6
25
2.41
1.24
1.2
1.4
0.50
1.28
%
—
6
18
118
991
1.23
1.24
3.5
3.4
0.81
0.83
ug/l
0.06
71
685
8
37
2.18
1.21
2.4
1.6
—
—
—
0
0
6
26
2.32
1.19
2.3
1.4
673.00
296.80
mu/l
—
6
20
7
30
2.35
1.12
1.0
1.2
—
—
—
0
0
9
165
0.54
1.09
3.0
4.9
—
—
—
0
0
7
33
2.13
1.06
1.3
1.8
1579.00
1615.94
ml
—
7
33
5
22
2.28
1.03
1.6
1.3
163.00
161.80
mmol/24h
—
5
22
14
84
1.68
0.98
1.6
1.4
29974.22
1194.71
e6/l
—
9
56
9
51
1.78
0.95
1.1
1.2
—
—
—
0
0
6
27
2.23
0.93
1.0
1.1
—
—
—
0
0
10
56
1.80
0.88
1.0
1.1
—
—
—
0
0
10
56
1.80
0.88
1.1
1.3
—
—
nmol/l
—
0
0
10
56
1.80
0.88
1.0
1.1
—
—
—
0
0
11
64
1.73
0.86
1.2
1.3
0.58
29.44
nmol/l
0.49
11
59
8
44
1.83
0.86
1.9
1.4
—
—
—
0
0
8
47
1.71
0.81
1.3
1.0
—
—
—
0
0
13
82
1.60
0.78
1.6
1.7
—
—
—
0
0
0
28
0.00
0.76
0.0
19.1
—
971.43
—
0
28
7
38
1.85
0.73
1.0
1.1
—
—
—
0
0
36
282
1.29
0.73
1.1
1.2
189.47
123.02
u/ml
0.29
12
109
9
57
1.59
0.71
1.3
1.7
9.20
9.80
%
—
9
57
18
127
1.43
0.68
1.8
1.6
2.09
55.86
iu/l
—
7
46
153
1387
1.14
0.68
1.4
1.4
—
—
—
0
0
83
719
1.18
0.68
1.3
1.4
—
—
—
0
0
10
155
0.64
0.66
4.5
3.1
8.00
7.52
mmol/l
—
10
150
7
44
1.60
0.65
1.4
1.3
—
—
—
0
0
5
88
0.56
0.56
1.0
1.2
1.37
1.58
g/l
—
5
88
8
55
1.46
0.56
2.0
1.8
—
—
—
0
0
15
107
1.41
0.55
2.9
1.8
36.73
43.10
nmol/l
0.55
15
100
11
74
1.50
0.53
2.0
1.6
—
—
—
0
0
10
66
1.52
0.52
1.5
1.8
—
—
—
0
0
10
66
1.52
0.52
1.3
1.1
—
—
—
0
0
11
78
1.42
0.43
2.0
1.6
—
—
—
0
0
11
78
1.42
0.43
2.0
1.6
—
—
—
0
0
11
78
1.42
0.43
2.0
1.6
—
—
—
0
0
0
16
0.00
0.41
0.0
1.9
—
—
—
0
0
0
17
0.00
0.40
0.0
1.9
—
—
—
0
0
12
88
1.37
0.40
2.9
1.8
157.67
224.83
pmol/l
2.37
12
83
0
18
0.00
0.40
0.0
2.1
—
91314.92
—
0
12
5
35
1.43
0.39
5.4
2.3
—
—
—
0
0
14
107
1.32
0.37
1.2
1.2
—
—
—
0
0
75
683
1.11
0.34
2.6
4.4
4.32
30.69
ug/l
1.45
62
567
15
186
0.80
0.31
3.6
3.0
1.53
1.63
mmol/l
0.32
15
181
7
97
0.72
0.31
1.3
1.3
0.89
0.89
g/l
—
7
97
7
55
1.28
0.30
1.1
1.1
1.80
1.56
nmol/l
—
7
47
10
129
0.77
0.28
7.3
3.7
24.86
25.62
mg/l
—
5
90
9
74
1.22
0.25
1.8
1.4
—
—
—
0
0
10
78
1.29
0.24
1.0
1.6
—
—
—
0
0
7
58
1.21
0.18
1.9
2.8
—
—
—
0
0
15
166
0.90
0.10
1.3
1.8
—
—
—
0
0
5
48
1.04
0.09
3.2
3.2
14.70
15.81
%
—
5
48
34
322
1.06
0.08
1.4
1.4
—
—
—
0
0
167
1664
1.00
0.00
3.4
3.4
—
—
—
0
0
18
184
0.98
0.00
1.0
1.1
—
—
—
0
0
19
189
1.01
0.00
25.9
10.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
7
70
1.00
-0.00
1.3
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.8
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint G6_POSTZOST and mortality.

Females

Parameter HR [95% CI] p-value
G6_POSTZOST 1.259 [1.07, 1.48] 0.005
Birth year 0.995 [0.99, 1.0] 0.291

During the follow-up period (1.1.1998 — 31.12.2019), 668 out of 1848 females with G6_POSTZOST died.

Males

Parameter HR [95% CI] p-value
G6_POSTZOST 1.483 [1.21, 1.82] < 0.001
Birth year 0.99 [0.98, 1.0] 0.031

During the follow-up period (1.1.1998 — 31.12.2019), 466 out of 1086 males with G6_POSTZOST died.

Mortality risk

Mortality risk for people of age

years, who have G6_POSTZOST.

N-year risk Females Males
1 0.109% 0.277%
5 0.642% 1.793%
10 1.732% 4.78%
15 3.376% 8.816%
20 6.006% 14.731%

Relationships between endpoints

↥

Index endpoint: G6_POSTZOST – Postzoster neuralgia

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data